黄芪治疗慢性心衰临床研究的系统评价及黄芪对能量转运影响的研究
|
摘要
慢性心力衰竭(chronic heart failure,CHF)是各种心血管系统疾病发展的终末阶段。随着人口的老龄化,CHF患病率不断升高,已经成为世界性的公共卫生问题。CHF防治指南的广泛应用,使其防治水平得到了很大提高,但病死率和致残率仍很高。很多科学家都在致力探寻更加有效的治疗方法,而针对心肌能量代谢方面的研究已经成为了其中的热点之一,不过目前尚缺乏公认有效的针对心肌能量代谢的特异性药物。
运用中药益气法治疗CHF的理念与改善衰竭心脏能量代谢有共通之处,近年来进行了很多有关的临床和实验研究,取得了较肯定的疗效。但这些研究尚未得到系统的评价,在一定程度上制约了其推广和应用。黄芪注射液是益气药的代表药——黄芪的提取物,目前在临床上被广泛用于治疗CHF。本文选择有关该药治疗CHF的临床研究文献进行系统评价和Meta分析,并通过细胞和分子生物学实验探讨其干预作用机制与心肌细胞能量转运的关系,以期为益气法治疗CHF提供循证和实验依据,同时也为寻找改善心肌能量代谢的药物做出有益的探索。
一、黄芪注射液治疗CHF临床研究的系统评价和Meta分析
方法:(1)以“(题目:黄芪注射液)and(题目:心功能不全or心衰or心力衰竭)—限定:人类”为检索式检索中国生物医学文献数据库,不限制年限;(2)由2位研究者独立进行文献筛选,意见不统一者通过讨论达到一致;(3)获取文献的相关研究特征资料,并加以评价;(4)对合格的随机对照试验(randomized blind controlled trial,RCT),进行Meta分析。
结果:(1)共检索到246篇文献;(2)经过两次筛选,剔除不符合纳入标准的文献,最终共117篇文献入选评价;(3)入选文献的研究设计普遍存在缺陷,有8篇文献的Jadad评分为1分,2篇为2分,没有文献得分在2分以上,将这10篇文献,即10个RCT纳入Meta分析,总样本量为711例。(4)Meta分析结果显示,加用黄芪注射液,可以更有效的提高左室射血分数(left ventricularejection fraction,LVEF)(P＜0.001)、短轴缩短率(fraction shortening,FS)(P＜0.00001)、心脏指数(cardiac index,CI)(P＜0.00001)、心输出量(cardiac output,CO)(P＜0.00001)和临床总有效率(P＜0.001);对采用单平面改良的Simpson法测量的两个RCT的结果合并后结果提示加用黄芪注射液对LVEF的影响无统计学意义(P=0.67);加用黄芪注射液与加用硝酸甘油对比,死亡率和心律失常发生率的差异无统计学意义(P值均＞0.05);加用黄芪注射液对左室舒张末期容积(P=0.17)、左室收缩末期容积(P=0.21)和二尖瓣E/A(P=0.75)的影响均无统计学意义。
结论:上述分析结果提示在常规治疗基础上加用黄芪注射液可更好地改善CHF患者的心功能。不过根据目前的Meta分析尚不能得出最终结果,真正评价黄芪注射液治疗CHF的疗效还需要大样本、多中心的严格设计的高质量RCT。黄芪注射液治疗CHF的临床研究的方法学质量还有待进一步提高。以下几个方面还有待提高:严格确定研究对象;加强辨证论治的应用;探索合适的阳性对照药或安慰剂和可行的盲法执行方案;选择恰当的疗效评价指标,建立完善的疗效评价体系;完整的随访和不良反应报告。
二、黄芪注射液对肥大心肌细胞能量转运的影响
方法:体外原代培养乳鼠心肌细胞,运用血管紧张素Ⅱ(angiotensin,AngⅡ)刺激心肌细胞,建立肥大心肌细胞模型。实验分为4组:空白组、模型组、络沙坦组和黄芪注射液组。在24h和48h两个时点,用共聚焦显微镜观察心肌细胞线粒体膜电位(mitochondrial membrane potential,MMP)及黄芪注射液的干预作用;采用生化法和高速电泳法观察肥大心肌细胞中总肌酸激酶活性和同功酶组成的变化和黄芪注射液的干预作用;运用RT-PCR法观察肥大心肌细胞肌酸激酶(creatine kinase,CK)同功酶和腺苷酸转位酶(adenine nucleotide translocator,ANT)异构体mRNA表达的影响和黄芪注射液的干预作用。
结果:(1)24h,模型组MMP较空白组显著下降(P＜0.01),各用药组较空白组上升,黄芪注射液组与空白组差异有统计学意义(P＜0.01);48h,模型组MMP较前进一步下降,与其余各组的差异均有统计学意义(P＜0.01),各用药组MMP则趋于正常:(2)ANT的异构体ANT1在肥大心肌细胞中的mRNA表达呈下降趋势,在48h下降明显(P＜0.01),而黄芪注射液有维持其水平的作用。ANT2 mRNA表达水平在肥大心肌细胞未发生明显变化,黄芪注射液在24h有提高其表达水平的作用(P＜0.01),48h各组间的差异无统计学意义;(3)24h,模型组和各用药组的CK-M亚基mRNA表达水平出现明显下降(P值均＜0.05),CK-MM所占比例也出现明显下降(P＜0.01),同时CK-B亚基mRNA表达水平和CK-BB所占比例均明显上升(P＜0.01),此时各组间CK-MB所占比例和总CK活性均无显著差异;48h,模型组CK-M亚基的mRNA表达继续下降(P＜0.01),各用药组的表达水平回升至正常水平,模型组和络沙坦组的CK-MM所占比例均继续下降(P值均＜0.01),而黄芪注射液组则回升至正常水平,模型组心肌细胞CK-B亚基mRNA表达继续上升(P＜0.01),其CK-BB所占比例仍偏高(P＜0.01),而各用药组均出现回落,黄芪注射液组恢复至正常水平,络沙坦组CK-MB比例较空白组显著升高(P＜0.05),模型组的CK活性出现了明显的下降(P＜0.01),而各用药组则维持在正常水平。
结论:肥大心肌细胞的MMP较正常心肌细胞明显下降,CK同功酶出现胚胎化改变,到衰竭期则出现ANT1的mRNA表达和CK的总活性降低,说明能量代谢尤其是能量物质转运出现异常。在络沙坦或黄芪注射液的干预下这些变化有所改善。结合上述临床研究的系统评价和实验部分研究,我们推断,黄芪注射液提高CHF患者心功能的机制,有可能与稳定能量物质转运酶系和MMP,从而改善心肌细胞舒缩功能有关。
Chronic heart failure(CHF) is the end-stage of all sort of heart disease.As the population is aging,morbidity rate of CHF is getting higher and higher,which becomes a international problem of public health.The guidelines for CHF improve the level of treating CHF,but the mortality and morbidity is still high.The unsatisfactory therapy effect makes people search for better method for treating CHF, the energy metabolism of cardiomyocyte is one of the hot spots,though there is not any generally acknowledged medicine which is against this target.
The principle of Traditional Chinese medicine,which treat CHF by replenishing Qi,has something in common with improving the of energy metabolism of failed heart.In resent decades,a lot of clinical and experimental trials have been carried out, which showed us the satisfactory results.But these results have not been systematically evaluated,the generalization and utilization of which is limited up to a certain extent.Radix astragali injection is the extractive of Radix astragali which is the deputy medicine of Qi-tonics.This injection is being generally used for treating CHF.In this thesis,a systematic review of clinical studies on treating CHF with Radix astragali injection will be performed,and some cellular and molecular biological experiments will be executed to investigate the relationship of mechanism of treating with Radix astragali injection and energy transportation of cardiomyocyte.We are aimed to find some evidence-base clinical and experimental evidence for treating CHF by replenishing Qi,and do some significant exploration in searching for the medicine which is able to improving energy metabolism of cardiomyocyte.
1 Radix astragali injection for CHF:a systematic review and meta analysis
Methods:(1)Search items were:(Title:Radix astragali injection) AND(Title: cardiac insufficiency or heart failure or cardiac failure),the search was applied to the CBM database(the publication date was not limited);(2)Literature bolting was performed by 2 reviewers independently,different opinions would be solved through negotiation;(3)The relation data of literatures were extracted and evaluated;(4)A meta analysis was performed based on qualified randomized blind controlled trials(RCTs).
Results:(1) 246 literatures were found out;(2) Through twice bolting,there were 117 literatures met the evaluate procedure.(3) There were many defects in the enrolled literatures.There were 8 literatures' Jadad scores were 1,2 literatures' Jadad scores were 2,and there were not any literature's Jadad score was higher than 2. These 10 literatures contained 10 RCTs which were enrolled into Meta analysis (711.cases).(4) The result of analysis showed that compared with routine therapy, additional of use of Radix astragali injection could raise left ventricular ejection fraction(LVEF)(P＜0.001),cardiac output(CO)(P＜0.00001),cardiac index(CI)(P＜0.00001) and effective rate(P＜0.001) significantly,but not significantly compared with additional of use of nitroglycerine;Two RCTs which used Simpson method enrolled into Meta analysis,and the result showed that compared with routine therapy, additional use of Radix astragali injection couldn't raised LVEF significantly(P=0.67); Compared with additional use of nitroglycerine,additional use of Radix astragali injection couldn't lower the mortality and incidence of arrhythmia(P＞0.05);There was no significant difference between routine therapy and additional use of Radix astragali injection in left ventricular end diastolic or systolic volume and E/A(P=0.17, 0.21,0.75).
Conclusion:Additional use of Radix astragali injection could improve the function of heart more effectively.However,According to this Meta analysis,we can't get final answer.We need high qualitative multicenter clinical trial of which the sample is large to evaluate the therapy effective for treating CHF with Radix astragali injection.The clinical trials which treat CHF with Radix astragali injection should improve their technology quality.The following aspects should be improved,such as strict criterion for enrolling,treatment based on syndrome differentiation,searching for suitable positive control or placebo and the way for executing blind method, choosing proper index for evaluating therapy effective,establishing consummate system for evaluating therapy effective,complete follow-up and side-effect reports.
2 The effect of Radix astragali injection on energy metabolism of hypertrophic cardiomyocyte
Methods:To establish the model of hypertrophic cardiomyocyte,we stimulated the cardiomyocytes of neonatal rat which were primarily cultured in vitro with angiotensin(AngⅡ).The cardiomyocytes were divided into 4 groups:control group, model group,Losartan group and Radix astragali injection group.At 24h and 48h,We investigated the effects of AngⅡ,Losartan and Radix astragali injection,on mitochondrial membrane potential(MMP) of cardiomyocytes by confocal microscopy, on the activity of total creatine kinase(CK) by means of biochemistry method and on CK isoenzymes which were separated using Rapid Electrophoresis system,and on B-CK,M-CK,mi-CK,iso-adenine nucleotide translocator(ANT) mRNA gene expression by using RT-PCR.
Results:(1) At 24h,MMP of model group was obviously reduced compared with control(P＜0.01),Radix astragali injection and Losartan could raise MMP,MMP of the cardiomyocytes stimulated by Radix astragali injection was higher than control group significantly(P＜0.01);at 48h,MMP of model group was continually reduced significantly(P＜0.01),the difference among other groups was not significantly.(2) ANT 1 mRNA gene expression of hypertrophic cardiomyocytes were lower,at 48h the difference between model group and control Was significant(P＜0.01),and Radix astragali injection could remain it at the normal level.ANT 2 mRNA gene expressions of hypertrophic cardiomyocytes remained the same with the control.At 24h,Radix astragali injection could raise the level of ANT 2 mRNA gene expression significantly(P＜0.01) and at the 48h not significantly.(3) At 24h,the levels of CK-M mRNA gene expressions(P＜0.05) and the content of CK-MM(P＜0.01) of hypertrophic cardiomyocytes were reduced obviously,at the same time the levels of CK-B mRNA gene expressions and the content of CK-BB were raised significantly(P＜0.01).There were no difference in the content of CK-MB and total CK activity among these groups.At 48h,the level of CK-M mRNA gene expressions of model group was continually reduced,while the levels of the groups treated with Radix astragali injection and Losartan were normalized.The content of CK-MM of model group and L group were raised significantly(P＜0.01),while the content of the group treated with Radix astragali injection remained normal.The level of CK-B mRNA gene expressions and the content of CK-BB of model group were still high(P＜0.01), and there was no difference in the content of CK-BB among other groups.The content of CK-MB of L group was higher than control group obviously(P＜0.05).Total CK activity of model group was depressed significantly(P＜0.01),and Radix astragali injection and Losartan could prevent it from being reduced.
Conclusion:The MMP of hypertrophic cardiomyocytes were obviously reduced compared with control,while the activated fetal program made the content of CK change.The level of ANT 1 mRNA gene expressions and CK activity of failed cardiomyocytes decreased.These changes showed that dysfunction of energy metabolism especially energy transportation emerged.Losartan and Radix astragali injection could improved this dysfunction.According to research above,we infer that the mechanism of improving heart function with Radix astragali injection may be concern with stabilizing the enzymes used for transporting energy substances and MMP so as to improving diastolic and systolic function.
运用中药益气法治疗CHF的理念与改善衰竭心脏能量代谢有共通之处,近年来进行了很多有关的临床和实验研究,取得了较肯定的疗效。但这些研究尚未得到系统的评价,在一定程度上制约了其推广和应用。黄芪注射液是益气药的代表药——黄芪的提取物,目前在临床上被广泛用于治疗CHF。本文选择有关该药治疗CHF的临床研究文献进行系统评价和Meta分析,并通过细胞和分子生物学实验探讨其干预作用机制与心肌细胞能量转运的关系,以期为益气法治疗CHF提供循证和实验依据,同时也为寻找改善心肌能量代谢的药物做出有益的探索。
一、黄芪注射液治疗CHF临床研究的系统评价和Meta分析
方法:(1)以“(题目:黄芪注射液)and(题目:心功能不全or心衰or心力衰竭)—限定:人类”为检索式检索中国生物医学文献数据库,不限制年限;(2)由2位研究者独立进行文献筛选,意见不统一者通过讨论达到一致;(3)获取文献的相关研究特征资料,并加以评价;(4)对合格的随机对照试验(randomized blind controlled trial,RCT),进行Meta分析。
结果:(1)共检索到246篇文献;(2)经过两次筛选,剔除不符合纳入标准的文献,最终共117篇文献入选评价;(3)入选文献的研究设计普遍存在缺陷,有8篇文献的Jadad评分为1分,2篇为2分,没有文献得分在2分以上,将这10篇文献,即10个RCT纳入Meta分析,总样本量为711例。(4)Meta分析结果显示,加用黄芪注射液,可以更有效的提高左室射血分数(left ventricularejection fraction,LVEF)(P＜0.001)、短轴缩短率(fraction shortening,FS)(P＜0.00001)、心脏指数(cardiac index,CI)(P＜0.00001)、心输出量(cardiac output,CO)(P＜0.00001)和临床总有效率(P＜0.001);对采用单平面改良的Simpson法测量的两个RCT的结果合并后结果提示加用黄芪注射液对LVEF的影响无统计学意义(P=0.67);加用黄芪注射液与加用硝酸甘油对比,死亡率和心律失常发生率的差异无统计学意义(P值均＞0.05);加用黄芪注射液对左室舒张末期容积(P=0.17)、左室收缩末期容积(P=0.21)和二尖瓣E/A(P=0.75)的影响均无统计学意义。
结论:上述分析结果提示在常规治疗基础上加用黄芪注射液可更好地改善CHF患者的心功能。不过根据目前的Meta分析尚不能得出最终结果,真正评价黄芪注射液治疗CHF的疗效还需要大样本、多中心的严格设计的高质量RCT。黄芪注射液治疗CHF的临床研究的方法学质量还有待进一步提高。以下几个方面还有待提高:严格确定研究对象;加强辨证论治的应用;探索合适的阳性对照药或安慰剂和可行的盲法执行方案;选择恰当的疗效评价指标,建立完善的疗效评价体系;完整的随访和不良反应报告。
二、黄芪注射液对肥大心肌细胞能量转运的影响
方法:体外原代培养乳鼠心肌细胞,运用血管紧张素Ⅱ(angiotensin,AngⅡ)刺激心肌细胞,建立肥大心肌细胞模型。实验分为4组:空白组、模型组、络沙坦组和黄芪注射液组。在24h和48h两个时点,用共聚焦显微镜观察心肌细胞线粒体膜电位(mitochondrial membrane potential,MMP)及黄芪注射液的干预作用;采用生化法和高速电泳法观察肥大心肌细胞中总肌酸激酶活性和同功酶组成的变化和黄芪注射液的干预作用;运用RT-PCR法观察肥大心肌细胞肌酸激酶(creatine kinase,CK)同功酶和腺苷酸转位酶(adenine nucleotide translocator,ANT)异构体mRNA表达的影响和黄芪注射液的干预作用。
结果:(1)24h,模型组MMP较空白组显著下降(P＜0.01),各用药组较空白组上升,黄芪注射液组与空白组差异有统计学意义(P＜0.01);48h,模型组MMP较前进一步下降,与其余各组的差异均有统计学意义(P＜0.01),各用药组MMP则趋于正常:(2)ANT的异构体ANT1在肥大心肌细胞中的mRNA表达呈下降趋势,在48h下降明显(P＜0.01),而黄芪注射液有维持其水平的作用。ANT2 mRNA表达水平在肥大心肌细胞未发生明显变化,黄芪注射液在24h有提高其表达水平的作用(P＜0.01),48h各组间的差异无统计学意义;(3)24h,模型组和各用药组的CK-M亚基mRNA表达水平出现明显下降(P值均＜0.05),CK-MM所占比例也出现明显下降(P＜0.01),同时CK-B亚基mRNA表达水平和CK-BB所占比例均明显上升(P＜0.01),此时各组间CK-MB所占比例和总CK活性均无显著差异;48h,模型组CK-M亚基的mRNA表达继续下降(P＜0.01),各用药组的表达水平回升至正常水平,模型组和络沙坦组的CK-MM所占比例均继续下降(P值均＜0.01),而黄芪注射液组则回升至正常水平,模型组心肌细胞CK-B亚基mRNA表达继续上升(P＜0.01),其CK-BB所占比例仍偏高(P＜0.01),而各用药组均出现回落,黄芪注射液组恢复至正常水平,络沙坦组CK-MB比例较空白组显著升高(P＜0.05),模型组的CK活性出现了明显的下降(P＜0.01),而各用药组则维持在正常水平。
结论:肥大心肌细胞的MMP较正常心肌细胞明显下降,CK同功酶出现胚胎化改变,到衰竭期则出现ANT1的mRNA表达和CK的总活性降低,说明能量代谢尤其是能量物质转运出现异常。在络沙坦或黄芪注射液的干预下这些变化有所改善。结合上述临床研究的系统评价和实验部分研究,我们推断,黄芪注射液提高CHF患者心功能的机制,有可能与稳定能量物质转运酶系和MMP,从而改善心肌细胞舒缩功能有关。
Chronic heart failure(CHF) is the end-stage of all sort of heart disease.As the population is aging,morbidity rate of CHF is getting higher and higher,which becomes a international problem of public health.The guidelines for CHF improve the level of treating CHF,but the mortality and morbidity is still high.The unsatisfactory therapy effect makes people search for better method for treating CHF, the energy metabolism of cardiomyocyte is one of the hot spots,though there is not any generally acknowledged medicine which is against this target.
The principle of Traditional Chinese medicine,which treat CHF by replenishing Qi,has something in common with improving the of energy metabolism of failed heart.In resent decades,a lot of clinical and experimental trials have been carried out, which showed us the satisfactory results.But these results have not been systematically evaluated,the generalization and utilization of which is limited up to a certain extent.Radix astragali injection is the extractive of Radix astragali which is the deputy medicine of Qi-tonics.This injection is being generally used for treating CHF.In this thesis,a systematic review of clinical studies on treating CHF with Radix astragali injection will be performed,and some cellular and molecular biological experiments will be executed to investigate the relationship of mechanism of treating with Radix astragali injection and energy transportation of cardiomyocyte.We are aimed to find some evidence-base clinical and experimental evidence for treating CHF by replenishing Qi,and do some significant exploration in searching for the medicine which is able to improving energy metabolism of cardiomyocyte.
1 Radix astragali injection for CHF:a systematic review and meta analysis
Methods:(1)Search items were:(Title:Radix astragali injection) AND(Title: cardiac insufficiency or heart failure or cardiac failure),the search was applied to the CBM database(the publication date was not limited);(2)Literature bolting was performed by 2 reviewers independently,different opinions would be solved through negotiation;(3)The relation data of literatures were extracted and evaluated;(4)A meta analysis was performed based on qualified randomized blind controlled trials(RCTs).
Results:(1) 246 literatures were found out;(2) Through twice bolting,there were 117 literatures met the evaluate procedure.(3) There were many defects in the enrolled literatures.There were 8 literatures' Jadad scores were 1,2 literatures' Jadad scores were 2,and there were not any literature's Jadad score was higher than 2. These 10 literatures contained 10 RCTs which were enrolled into Meta analysis (711.cases).(4) The result of analysis showed that compared with routine therapy, additional of use of Radix astragali injection could raise left ventricular ejection fraction(LVEF)(P＜0.001),cardiac output(CO)(P＜0.00001),cardiac index(CI)(P＜0.00001) and effective rate(P＜0.001) significantly,but not significantly compared with additional of use of nitroglycerine;Two RCTs which used Simpson method enrolled into Meta analysis,and the result showed that compared with routine therapy, additional use of Radix astragali injection couldn't raised LVEF significantly(P=0.67); Compared with additional use of nitroglycerine,additional use of Radix astragali injection couldn't lower the mortality and incidence of arrhythmia(P＞0.05);There was no significant difference between routine therapy and additional use of Radix astragali injection in left ventricular end diastolic or systolic volume and E/A(P=0.17, 0.21,0.75).
Conclusion:Additional use of Radix astragali injection could improve the function of heart more effectively.However,According to this Meta analysis,we can't get final answer.We need high qualitative multicenter clinical trial of which the sample is large to evaluate the therapy effective for treating CHF with Radix astragali injection.The clinical trials which treat CHF with Radix astragali injection should improve their technology quality.The following aspects should be improved,such as strict criterion for enrolling,treatment based on syndrome differentiation,searching for suitable positive control or placebo and the way for executing blind method, choosing proper index for evaluating therapy effective,establishing consummate system for evaluating therapy effective,complete follow-up and side-effect reports.
2 The effect of Radix astragali injection on energy metabolism of hypertrophic cardiomyocyte
Methods:To establish the model of hypertrophic cardiomyocyte,we stimulated the cardiomyocytes of neonatal rat which were primarily cultured in vitro with angiotensin(AngⅡ).The cardiomyocytes were divided into 4 groups:control group, model group,Losartan group and Radix astragali injection group.At 24h and 48h,We investigated the effects of AngⅡ,Losartan and Radix astragali injection,on mitochondrial membrane potential(MMP) of cardiomyocytes by confocal microscopy, on the activity of total creatine kinase(CK) by means of biochemistry method and on CK isoenzymes which were separated using Rapid Electrophoresis system,and on B-CK,M-CK,mi-CK,iso-adenine nucleotide translocator(ANT) mRNA gene expression by using RT-PCR.
Results:(1) At 24h,MMP of model group was obviously reduced compared with control(P＜0.01),Radix astragali injection and Losartan could raise MMP,MMP of the cardiomyocytes stimulated by Radix astragali injection was higher than control group significantly(P＜0.01);at 48h,MMP of model group was continually reduced significantly(P＜0.01),the difference among other groups was not significantly.(2) ANT 1 mRNA gene expression of hypertrophic cardiomyocytes were lower,at 48h the difference between model group and control Was significant(P＜0.01),and Radix astragali injection could remain it at the normal level.ANT 2 mRNA gene expressions of hypertrophic cardiomyocytes remained the same with the control.At 24h,Radix astragali injection could raise the level of ANT 2 mRNA gene expression significantly(P＜0.01) and at the 48h not significantly.(3) At 24h,the levels of CK-M mRNA gene expressions(P＜0.05) and the content of CK-MM(P＜0.01) of hypertrophic cardiomyocytes were reduced obviously,at the same time the levels of CK-B mRNA gene expressions and the content of CK-BB were raised significantly(P＜0.01).There were no difference in the content of CK-MB and total CK activity among these groups.At 48h,the level of CK-M mRNA gene expressions of model group was continually reduced,while the levels of the groups treated with Radix astragali injection and Losartan were normalized.The content of CK-MM of model group and L group were raised significantly(P＜0.01),while the content of the group treated with Radix astragali injection remained normal.The level of CK-B mRNA gene expressions and the content of CK-BB of model group were still high(P＜0.01), and there was no difference in the content of CK-BB among other groups.The content of CK-MB of L group was higher than control group obviously(P＜0.05).Total CK activity of model group was depressed significantly(P＜0.01),and Radix astragali injection and Losartan could prevent it from being reduced.
Conclusion:The MMP of hypertrophic cardiomyocytes were obviously reduced compared with control,while the activated fetal program made the content of CK change.The level of ANT 1 mRNA gene expressions and CK activity of failed cardiomyocytes decreased.These changes showed that dysfunction of energy metabolism especially energy transportation emerged.Losartan and Radix astragali injection could improved this dysfunction.According to research above,we infer that the mechanism of improving heart function with Radix astragali injection may be concern with stabilizing the enzymes used for transporting energy substances and MMP so as to improving diastolic and systolic function.
引文
[1]Hunt SA,Abraham WT,Chin MH,et al.ACC/AHA 2005 Guideline Update for the Diagnosis and Management of ChronicHeart Failure in the Adult[J].Circulation,2005,112(12):e154-e235.
[2]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095.
[3]Task Force Members,Kenneth Dickstein,Alain Cohen-Solal,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine(ESICM)[J].Eur.Heart J,2008,29(19):2388-2442.
[4]McKee PA,Castelli WP,McNamara PM,et al.The natural history of congestive heart failure:the Framingham study[J].N Engl J Med,1971,285(26):1441-1446.
[5]张子彬,Tsung O.Cheng,张玉传.充血性心力衰竭学[M].第1版.北京:科学技术文献出版社,2002:223-224.
[6]胡大一.心力衰竭诊断进展[EB/OL].http://pkuph.365heart.com/html/11663.shtm-1,2006-03-08/2009-02-20.
[7]Pennell DJ,Sechtem UP Higgins CB,et al.Clinical indications for cardiovascular magnetic resonance(CMR):Consensus Panel report[J].J Cardiovasc Magn Reson,2004,6(4):727-765.
[8]Hendel RC,Patel MR,Kramer CM,et al.ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging:a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group,American College of Radiology,Society of Cardiovascular Computed Tomography,Society for Cardiovascular Magnetic Resonance,American Society of Nuclear Cardiology,North American Society for Cardiac Imaging,Society for Cardiovascular Angiography and Interventions,and Society of Interventional Radiology[J].J Am Coll Cardiol,2006,48(7):1475-1497.
[9]朱文玲.心力衰竭的进展-心力衰竭的临床和影像学诊断[J].中国循环杂志,2006,21(1):2.
[10]Roul G,Moulichon ME,Bareiss P,et al.Exercise peak VO_2 in chronic heart failure:is it still of value?[J].Eur Heart J,1994,15(4):495-502.
[11]Morales FJ,Montemayor T,Martinez A.Shuttle versus six-minute walk test in the prediction of outcome in chronic heart failure[J].Int J Cardiol,2000,76(2-3):101-105.
[12]Bittner V,Weiner DH,Yusuf S,et al.Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction[J].JAMA,1993,270(14):1702-1707.
[13]Roul G,Germain P,Bareiss P,et al.Does the 6-minute walk test predictsthe prognosis in patients with NYHA class Ⅱ or Ⅲ chronic heart failure[J].Am Heart J,1998,136(3):139-457.
[14]Troosters T,Gosselink R,Decramer M.Six minute walking distance in healthy elderly subjects[J].Eur Respir J,1999,14(2):270-274.
[15]王新房.超声心动图学[M].第3版.北京:人民卫生出版社,1999:278-281.
[16]Nikitin NP,Loh PH,Silva R,et al.Prognostic value of systolic mitral annular velocity measured with Doppler tissue imaging in patients with chronic heart failure caused by left ventricular systolic dysfunction[J].Heart,2006,92(6):775-779.
[17]Sudoh T,Kangwa K,Minamion N,et al.A new natriuretic peptide in porcine brain[J].Nature,1988,332(6159):78.
[18]尹欣,吴春旭,徐丹丹.血浆脑钠素水平与心衰患者左心功能关系的临床研究[J].标记免疫分析与临床,2005,12(2):76-77,81.
[19]卢敏,张梦玺,曹军香.心力衰竭患者脑钠肽、C反应蛋白与心功能的关系[J].实用医学杂志,2007,23(5):658-660.
[20]Maisel AS,Koon J,Krishnaswamy P,et al.Utility of B-natriuretic pepetide as a rapid,point-of care test foscreening patients undergoing echocardiography todetermine left ventricular dysfunction[J].Am Heart J,2001,141(3):367-3741
[21]Maisel AS,Krishnaswamy P,Nowak RM,et al.Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J].N Engl J Med,2002,347(3):161-167.
[22]Dao Q,Krishnaswamy P,Kazanegra R,et al.Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting[J].J Am Coll Carol,2001,37(2):379-385.
[23]Richards AM,Nicholls MG,Espiner EA,et al.B-type natriuretic peptide and ejection fraction for prognosis after myocardial infarction[J].Circulartion,2003,107(22):2786-2792.
[24]Bettencourt P,Ferreira A,Dias P,et al.Evaluation of brain natriuretic peptide in the diagnosis of heart failure[J].Cardiology,2000,93(1):19-25.
[25]Suzuki T,Yamaoki K,Nakajima O,et al.Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic;peptide levels[J].Jpn Heart J,2000,41(2):205-214.
[26]Nielsen OW,McDonagh TA,Robb SD,et al.Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population[J].J Am Coll Cardiol,2003,41(1):113-120.
[27]Maisel A.B-type natriuretic peptide levels:diagnostic and prognostic in congestive heart failure:what's next?[J].Circulation,2002,105(20):2392-2397.
[28]Marantz PR,Tobin JN,Wassertheil-Smoller S,et at.The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria[J].Circulation,1988,77(3):607-612.
[29]吴学思.心力衰竭的进展-慢性心力衰竭的主要进展概述-半个世纪的变迁[J].中国循环杂志,2005,20(5):323-324.
[30]The CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure.Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)[J].N Engl J Med,1987,316(23):1429-1435.
[31]The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure[J].N Engl J Med,1991,325(5):293-302.
[32]Cohn JN,Johnson G,Ziesche S,et al,A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure[J].N Engl J Med,1991,325(5):303-310.
[33]The SOLVD Investigators.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions[J].N Engl J Med,1992,327(10):685-691.
[34]McAlister FA,Stewart S,Ferrua S,et al.Multidisciplinary strategies for the management of heart failure patients at high risk for admissions systematic review of randomized trials[J].J Am Coll Cardiol,2004,44(4):810-819.
[35]Majumdar SR,McAlister FA,Cree M,et al.Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS)study [J].Clin Ther.2004,26(5):694-703.
[36]Cohn JN,Tognoni G.A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure[J].N Engl J Med,2001,345(23):1667-1675.
[37]McMurray JJ,Ostergren J,Swedberg K,et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-c-onverting-enzyme inhibitors:the CHARM-Added trial[J].Lancet,2003,362(9386):767-771.
[38]Pitt B,Segal R,Martinez FA,et al.Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study,ELITE)[J].Lancet,1997,349(9054):747-752.
[39]McKelvie RS,Yusuf S,Pericak D,et al.Comparison of candesartan,enalapril,and their combination in congestive heart failure:randomized evaluation of strategies for left ventricular dysfunction (RESOLVD)pilot study[J].Circulation,1999,100(10):1056-64.
[40]Pitt B,Poole-Wilson PA,Segal R,et al.Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomised trial-the Losartan Heart Failure Survival Study ELITE Ⅱ[J].Lancet,2000 355(9215):1582-1587.
[41]Dickstein K,Kjekshus J.OPTIMAAL Steering Committee of the OPTIMAAL Study Group,Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial.Optimal Trial in Myocardial Infarction with Angiotensin Ⅱ Antagonist Losartan[J].Lancet,2002,360(9335):752-760.
[42]Velazquez EJ,Pfeffer MA,McMurray JV,et al.Valsartan in acute myocardial infarction (VALIANT)trial:baseline characteristics in context[J].Eur J Heart Fail,2003,5(4):537-544.
[43]Bohm M,Baumhakel M,Probstfield JL,et al.Sexual function,satisfaction,and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients:substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND)[J].Am Heart J,2007,154(1):94-101.
[44]Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])[J].Am J Cardiol,1996,78(8):902-907.
[45]Pitt B,Zannad F,Remme WJ,et al.The effect of spironolactone on morbidity and mortality in parients with severe heart failure.For the RALEA Ivestigator[J].N Engl Med,1999,341(10):709-717
[46]Waagstein F,Bristow MR,Swedberg K,et al.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.Metoprolol in Dilated Cardiomyopathy (MDC)Trial Study Group[J].Lancet,1993,342(8885):1441-1446.
[47]CIBIS Investigators and Committees.A randomized trial of beta-blockade in heart failure.The Cardiac Insufficiency Bisoprolol Study (CIBIS)[J].Circulation,1994,90(4):1765-73.
[48]Colucci WS,Packer M,Bristow MR,et al.Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure.US Carvedilol Heart Failure Study Group[J].Circulation,1996,94(11):2800-2806.
[49]Packer M,Fowler MB,Roecker EB,et al.Effect of carvedilol on the morbidity of patients with severe chronic heart failure:results of the carvedilol prospective randomized cumulative survival (COPERNICUS)study[J].Circulation,2002,106(17):2194-2199.
[50]Hjalmarson A,Goldstein S,Fagerberg B,et al.Effects of controlled-release metoprolol on total mortality,hospitalizations,and well-being in patients with heart failure:the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF).MERIT-HF Study Group[J].JAMA,2000,283(10):1295-1302.
[51]CIBIS-Ⅱ investigator and committees.The Cardiac Insufficiency Bisoprolol Study Ⅱ (CIBIS-Ⅱ):a randomised trial[J].Lancet,1999,353(9146):9-13.
[52]Flather MD,Shibata MC,Coats AJS,et al.Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)[J].Eur Heart J,2005,26(3):215-225.
[53]Willenheimer R,van Veldhuisen DJ,Silke B,et al.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBTS)Ⅲ[J].Circulation,2005,12(16):2426-2435.
[54]Uretsky BF,Young JB,Shahidi FE,et al.Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure:results of the PROVED trial.PROVED Investigative Group[J].J Am Coll Cardiol,1993,22(4):955-962.
[55]Packer M,Gheorghiade M,Young JB,et al.Withdrawal of digox-in from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors:RADIANCE Study[J].N Enel J Med,1993,329(1):l-7.
[56]The Digitalis Investigation Group.The effect of digoxin on mortality and morbidity in patients with heart failure[J].N Engl J Med,1997,336(8):525-533.
[57]Ahmed A,Rich MW,Love TE,et al.Digoxin and reduction in mortality and hospitalization in heart failure:a comprehensive post hoc analysis of the DIG trial[J].Eur Heart J,2006,27(2):178-186.
[58]Neuberg GW,Miller AB,O'Connor CM,et al.Diuretic resistance predicts mortality in patients with advanced heart failure[J].Am Heart J,2002,144(1):31-38.
[59]Sakai S,Mivauchi T,Kebayashi M,et al.Inhibition of myocardial endothelin pathway improves long-term survival in heart failures[J].Nature,1996,384(6607):353-355.
[60]Torre-Amione G,Young JB,Durand J,et al.Hemodynamic effects of tezosentan,an intravenous dual endothelin receptor antagonist,in patients with class Ⅲ to IV congestive heart failure[J].Circulation,2001,103(7):973-980.
[61]Schalcher C,Cotter G,Reisin L,et al.The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failures [J].Am Heart J,2001,142(2):340-349.
[62]GuillermoTA,JamesB,Wilson S,et al.Hemodynamic and clinical effects of tezosentan,an intravenous dual endothelin receptor antagonist,in patients hospitalized for acute decompensated heart failure[J].J Am Coll Cardiol,2003,42(1):140-147.
[63]Cowburn PJ,Cleland JG,McArthur JC,et al.Short-term haemodynamic effects of BQ-123,a selective endothelin ET(A)-receptor antagonist,in chronic heart failure[J].Lancet,1998,352(9123):201-202.
[64]Kim NN,Dhir V,Azadzoi KM,et al.Pilot study of the endothelin-A receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction[J].J Androl,2002,23(1):76-83.
[65]Spieker LE,Mitrovic V,Noll G,et al.Acute hemodynamic and neurohumoral effects of selective ET(A)receptor blockade in patients with congestive heart failure.ET 003 Investigators[J].J Am Coll Cardiol,2000,35(7):1745-1752.
[66]Poole-Wilson P,Colucci N,Massie B,et al.Heart Failure:Scientific Principles and Clinical Practice[M].New York:Churchill Livingstone,1997:155-171.
[67]许顶立,任吴,充血性心力衰竭水潴留的机制—Aquaporin2水通道蛋白的作用,[J],2000,31(2)：150-152．
[68]Recio-Mayoral A,Kaski JC,McMurray JJ,et al.Clinical trials update from the European Society of Cardiology Congress in Vienna,2007:PROSPECT,EVEREST,ARISE,ALOFT,FINESSE,Prague-8,CARESS in MI and ACUITY[J].Cardiovasc Drugs Ther,2007,21(6):459-465.
[69]Keating GM,Goa KL.Nesiritide:a review of its use in acute decompensated heart failure[J].Drugs,2003,63(1):47.
[70]Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF).Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial[J].JAMA,2002,287(12):1531-1540.
[71]Yancy CW,Saltzberg MT,Berkowitz RL,et al,Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial)[J].Am J Cardiol 2004,94(5):595-601.
[72]Peacock WF 4th,Fonarow GC,Emerman CL,et al.Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE[J].Cardiology,2007,107(1):44-51.
[73]Moazami N,Damiano RJ,Bailey MS,et al.Nesiritide (BNP)in the management of postoperative cardiac patients[J].Ann Thorac Surg,2003,75(6):1974-1976.
[74]Takaoka H,Takeuchi M,Hata K,et al.Beneficial effects of a Ca~(2+)sensitizer,MCI-154,on the myocardial oxygen consumption cardiac output relation in patients with left ventricular dysfunction after myocardial infarctionxomparison with dobutamine and phosphodiesterase inhibitor[J].Am Heart J,1997,133(3):283-289.
[75]Mori M,Takeuchi M,Takaoka H,et al.Lusitropic effects of a Ca~(2+)sensitization with a new cardiotonic agent,MCI-154,on diseased human hearts[J].Cardiovasc Res,1995,30(6):915-922.
[76]Follath F,Cleland JG,Just H,et al.Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study):a randomised double-blind trial[J].Lancet,2002,360(9328):196-202.
[77]Moiseyev VS,Poder P,Andrejevs N,et al.Safety and efficacy of a novel calcium sensitizer,levosimendan,in patients with left ventricular failure due to an acute myocardial infarction.A randomized,placebo-controlled,double-blind study (RUSSLAN)[J].Eur Heart J,2002,23(18):1422-1432.
[78]Fazio S,Sabatini D,Capaldo B,et al.A preliminary study of growth hormone in the treatment of dilated cardiomyopathy[J].N Engl J Med,1996,334(13):809-814.
[79]Osterziel KJ,Strohm O,Schuler J,et al.Randomised,double-blind,placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy[J].Lancet,1998,351(9111):1233-1237.
[80]Isgaard J,Bergh CH,Caidahl K,et al.A placebo-controlled study of growth hormone in patients with congestive heart failure[J].Eur Heart J,1998,19(11):1704-1711.
[81]谭真,刘兴斌.心脏再同步治疗研究现状[J].心血管病学进展,2008,29(2):228-231.
[82]Cazeau S,Ritter P,Bakdach S,et al.Four chamber pacing in dilated cardiomyopathy[J].Pacing Clin Electrophysiol,1994,17(11 Pt 2):1974-1979.
[83]Anand IS,(2arson P,Galle E,et al.Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure:results from the Comparison of Medical Therapy,Pacing and Defibrillation in Heart Failure(COMPANION) trial[J].Circulation.2009,119(7):969-977.
[84]Cleland JG,Daubert JC,Erdmann E,et al.The effect of cardiac resynchronization on morbidity and mortality in heart failure[J].N Engl J Med,2005,352(15):1539-1549.
[85]Rossi A,Rossi G,Piacenti M,et al.The current role of cardiac resynchronization therapy in reducing mortality and hospitalization in heart failure patients:a meta-analysis from clinical trials[J].Heart Vessels,2008,23(4):217-23.
[86]Vardas PE,Auricchio A,Blanc JJ,et al.Guidelines for cardiac pacing and cardiac resynchronization therapy:The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology.Developed in collaboration with the European Heart Rhythm Association.[J].Eur Heart J,2007,28(18):2256-2295.
[87]Gasparini M,Auricchio A,Regoli F,et al.Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression:the importance of performing atrioventricular junction ablation in patients with atrial fibrillation[J].J Am Coll Cardiol,2006,48(4):734-743.
[88]Greenberg H,Case RB,Moss AJ,et al.Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial(MADIT-Ⅱ)[J].J Am Coll Cardiol,2004,43(8):1459-1465.
[89]Bardy GH,Lee KL,Mark DB,et al.Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure[J].N Engl J Med,2005,352(3):225-237.
[90]Wilkoff BL,Cook JR,Epstein AE,et al.Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator:the Dual Chamber and VVI Implantable Defibrillator(DAVID) Trial[J].JAMA,2002,288(24):3115-23.
[91]Dec GW.Management of heart failure:crossing boundary over to the surgical country[J].Surg Clin North Am,2004,84(1):1-25.
[92]胡盛寿,郑哲.心力衰竭的进展(9)终末期心力衰竭的外科治疗[J].中国循环杂志,2006,21(4):243-245.
[93]Dec GW.Management of heart failure;crossing boundary over to the country[J].Surg Clin N Am,2004,84(1):1-25.
[94]Rose EA,Gelijns AC,Moskowitz AJ,et al.Long-term mechanical left ventricular assistance for end-stage heart failure[J].N Engl J Med,2001,345(20):1435-1443.
[95]Curtis JP,Sokol SI,Wang Y,et al.The association of left ventricular ejection fraction,mortality,and cause of death in stable outpatients with heart failure[J].J Am Coll Cardiol,2003,42(4):736-742.
[96]de Bold AJ,Bruneau BG,Kuroski de Bold ML.Mechanical and neuroendocrine regulation of the endocrine heart[J].Cardiovasc Res,1996,31(1):7-18.
[97]Clerico A,Iervasi G,Del Chicca MG,et al.Circulating levels of cardiac natriuretic peptides (ANP and BNP)measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure[J].J Endocrinol Invest.1998,21(3):170-179.
[98]Wallen T,Landahl S,Hedner T,et al.Brain natriuretic peptide predicts mortality in the elderly[J].Heart 1997,77(3):264-267.
[99]Cheng V,Kazanagra R,Garcia A,et al.A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure:a pilot study[J].J Am Coll Cardiol,2001,37(2):386-391.
[100]Doust JA,Pietrzak E,Dobson A,et al.How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure:systematic review[J].BMJ,2005,330(7492):625.
[101]Murdoch DR,McDonagh TA,Byrne J,et al.Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration:randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy [J].Am Heart J,1999,138(6 Pt 1):1126-1132.
[102]Beck-da-Silva L,de Bold A,Fraser M,et al.BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure[J].Congest Heart Fail,2005,11(5):248-53;quiz 254-255.
[103]Guyatt GH.Measurement of health-related quality of life in heart failure[J].J Am Coll Cardiol,1993,22(4 SupplA):185A-191A.
[104]Morgan K,McGee H,Shelley E.Quality of life assessment in heart failure interventions:a 10-year (1996-2005)review[J].Eur J Cardiovasc Prev Rehabil,2007,14(5):589-607.
[105]Garin O,Ferrer M,Pont A,et al.Disease-specific health-related quality of life questionnaires for heart failure:a systematic review with meta-analyses [J].Qual Life Res,2009,18(1):71-85.
[106]Heo S,Moser DK,Riegel B,et al.Testing the psychometric properties of the Minnesota Living with Heart Failure questionnaire [J].Nurs Res,2005,54(4):265-272.
[107]O'Keeffe ST,Lye M,Donnellan C,et al.Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients[J].Heart,1998,80(4):377-382.
[108]Cahalin L,Mathier M,Semigran M,et al.The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure[J].Chest,1996,110(2):325-332.
[109]Solway S,Brooks D,Lacasse Y,et al.A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain[J].Chest,2001,119(1):256-270.
[110]Opasich C,Pinna GD,Mazza A,et al.Six-minute walking performance in patients with moderate-to-severe heart failure:Is it a useful indicator in clinical practice?[J].Eur Heart J 2001,22(6):488-496.
[111]Olsson LG,Swedberg K,Clark AL,et al.Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized,blinded intervention trials of chronic heart failure:a systematic review[J].Eur Heart J.2005,26(8):778-793.
[112]ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.ATS Statement:Guidelines for the Six-Minute Walk Test[J].Am J Respir Crit Care Med.2002,166(1):111-117.
[113]Ishino M,Takeishi Y,Niizeki T,et al.Risk stratification of chronic heart failure patients by multiple biomarkers:implications of BNP,H-FABP,and PTX3[J].Circ J,2008,72(11):1800-1805.
[114]Dokainish H.Combining tissue Doppler echocardiography and B-type natriuretic peptide in the evaluation of left ventricular filling pressures:review of the literature and clinical recommendations[J].Can J Cardiol,2007,23(12):983-989.
[115]Castellanos LR,Bhalla V,Isakson S,et al.B-type natriuretic peptide and impedance cardiography at the time of routine echocardiography predict subsequent heart failure events[J].J Card Fail,2009,15(1):41-47.
[107]顾东风,黄广勇,何江,等.中国心力衰竭流行病学调查及其患病率[J].中华心血管病杂志,2003,31(10):3-6.
[1]国家药典委员会.中华人民共和国药典[M].北京:化学工业出版社,2005:232-233.
[2]张慧.黄芪注射液治疗小儿病毒性心肌炎107例疗效分析[J].中国保健医学研究版,2008,16(14):687-688.
[3]于凤秀.黄芪注射液治疗急性病毒性心肌炎的临床观察[J].中西医结合心脑血管病杂志,2008,6(9):1100-1101.
[4]刘慧玲,赵卫国.黄芪注射液治疗病毒性心肌炎疗效观察[J].2008,17(3):329-332
[5]杨顺昱.黄芪注射液合用环磷腺苷葡胺治疗急性病毒性心肌炎的疗效观察[J].广西医学,2008,30(5):649-650.
[6]陈晓培,张耕.黄芪注射液治疗小儿病毒性心肌炎疗效观察[J].中国医院药学杂志,2007,27(9):1270-1271.
[7]刘冰,张辉.黄芪注射液佐治病毒性心肌炎疗效观察[J].中国妇幼保健,2005,20(20):2697-2698.
[8]宁亚兰,郭霞.黄芪注射液治疗急性病毒性心肌炎51例[J].陕西医学杂志,2005,34(6):729-730.
[9]苏群,方强.黄芪注射液联用西药治疗急性病毒性心肌炎对血自然杀伤细胞活性及可溶性白介素-2受体水平的影响[J].中国中西医结合急救杂志,2000,7(2):75.
[10]沈菊英,龚祖埙,杨英珍,等.黄芪对培养的大鼠搏动心肌细胞感染柯萨奇B_2病毒后保护作用的超微观察[J].细胞生物学杂志,1986,(2):87-89.
[11]郭棋,彭天庆,杨英珍,等.黄芪对柯萨奇B3病毒感染培养大鼠心肌细胞Ca2+内流及该病毒RNA复制的影响[J].中国中西医结合杂志,1995,15(8):483.
[12]蒋丽敏,魏克伦,李微,等.黄芪注射液对柯萨奇B3心肌炎小鼠心肌穿孔素表达[J].中成药,2002,24(11):857-859.
[13]曹洪欣,刘寨华,张华敏.基于聚类分析的病毒性心肌炎证候分类及证候特征研究[J].2007,48(7):629-632.
[14]林谦,王硕仁,吕唏莹,等.党参黄芪治疗心气虚型冠心病的初步观察[J].北京中医,1990,12(1):33.
[15]姚萍,雷艳蓉,唐恩东.黄芪注射液治疗冠心病心绞痛的临床观察[J].四川中医,2004,22(7):52-53.
[16]王翠兰,胡英华,张蕾,等.黄芪注射液对冠心病患者血液流变性的影响[J].微循环学杂志,2000,10(1):50.
[17]张彦梅.黄芪注射液对冠心病左心室收缩功能的影响山西医学杂志[J].1997,26(5):424-425.
[18]曹志军,杨汉光.大剂量黄芪注射液治疗冠心病心纹痛68例临床观察[J].北京中医,1997,16(3):27-29.
[19]韩光辉.大剂量黄芪注射液治疗冠心病88例[J].河南医科大学学报,1999,34(4):85.
[20]刘建勤.黄芪注射液治疗冠心病心绞痛的临床研究[J].时珍国医国药,2007, 18(9):2259-2260.
[21]李乙根.黄芪注射液联合川芎嗪注射液治疗冠心病不稳定型心绞痛46例临床观察[J].2008,40(6):35-36.
[22]单乃静.普泽川芎嗪合黄芪注射液治疗冠心病心绞痛60例疗效观察[J].时珍国医国药,2004,15(8):506-507.
[23]王兴,陈蓉,刘宝红.黄芪注射液治疗冠心病心绞痛及其对血浆vWF、CEC的影响[J].上海中医药杂志,2005,39(7):12-13.
[24]徐军,黄象娟,齐法莲,等.络泰和黄芪注射液对冠心病患者血浆中ET-1和vWF的影响[J].中国免疫学杂志,2003,19(2):128.
[25]陈志群,郭梅煌,马建芳,等.黄芪注射液对冠心病患者C反应蛋白和体液免疫的影响[J].使用中西医结合临床,2001,1(1):3-4.
[26]易思,劳卫国,李燕.黄芪注射液合复方丹参注射液为主治疗肺心病45例疗效观察[J].新中医,2002,34(7):30-31.
[27]杨芝芸.黄芪注射液治疗高原肺心病心衰65例[J].辽宁中医杂志,1997,24(6):261.
[28]韩舒秀,郑晓兰.老年慢性肺心病患者脂质过氧化损伤与病情演变的关系[J].中国医学研究与临床.2004,2(2):64-65.
[29]赵淑杰.硝酸甘油联合黄芪注射液治疗肺心病心功能不全的临床观察[J].吉林医学,2007,28(10):1224.
[30]刘浩,陈爱萍.黄芪注射液对慢性肺心病患者血中脂质过氧化物及抗氧化酶活性的影响[J].中国医院药学杂志,2006,26(11):1340-1342.
[31]高殿富.黄芪注射液对肺心病病人超氧化物歧化酶水平的影响[J].中国新药与临床杂志,1999,18(6):376-377.
[32]余静,郭雪娅,赵锋,等.黄芪注射液对高血压病患者血浆P选择素、血栓素B2及6-酮前列环素F1α的影响[J].临床荟萃,2005,20(13):721-722.
[33]郭惠莲.复方丹参和黄芪注射液辅助治疗肺心病的疗效[J].第四军医大学学报,2003,24(14):封3.
[34]李洪涛.低分子量肝素联合地奥黄芪注射液治疗肺心病30例临床观察[J].中原医刊,2005,32(8):39-40.
[35]郭健,施慧娟.丹参黄芪注射液配合西药治疗肺心病的急性发作期42例[J].陕西中医,2002,23(10):879-880.
[36]朱子阳.黄芪注射液辅助治疗肺心病急性加重期的临床观察[J].中国中西医结合杂志,2001,21(4):268.
[37]梁晶,熊岳玲.黄芪注射液治疗肺心病疗效观察[J].中药药理与临床,1999,15(6):43-44.
[38]周波,张小燕,常中凡,等.黄芪注射液辅助治疗肺心病心力衰竭64例[J].1999,18(6):374-375.
[39]张忠德,黄东晖,毛炜,等.黄芪注射液对肺心病患者血清地高辛浓度的影响[J].新中医,1999,31(4):35-36.
[40]张莹,梁晋普,指导:郭维琴.郭维琴教授治疗病态窦房结综合征经验拾萃[J].实用中医内科杂志,2005,19(3):210.
[41]马玲.参附黄芪注射液治疗病态窦房结综合征23例[J].医药论坛杂志.2005,26(22):43.
[42]邱勇.温阳活血饮配合黄芪注射液治疗病态窦房结综合征31例[J].福建中医药,2003,34(1):29.
[43]郑新玲.黄芪注射液治疗病态窦房结综合征疗效观察[J].中西医结合实用临床急救,1999,6(3):133-134.
[44]王宏伟,郭芳,谢岩屏.黄芪注射液治疗冠心病所致病窦综合征40例[J].中国中医药信息杂志,1999,6(12):56.
[45]黄平东.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4):592-593.
[46]李南夷,邓铁涛,文旺秀.心衰证治研究概述[J].中医药信息,1995,(5):6-10.
[47]黄平东,罗懿明,黄衍寿,等.充血性心力衰竭中医证型特征及其演变规律的临床观察[J].中西医结合心脑血管病杂志,2000,1(12):685-686.
[48]任澎,程祖亨,马依彤.黄芪注射液对充血性心力衰竭患者的急性血液动力学效应[J].中国中西医结合杂志,1998,18(8):460.
[49]张金国,高东升,谭洪勇,等.黄芪注射液对老年充血性心力衰竭患者血浆促炎性细胞因子的影响[J].济宁医学院学报,2006,29(2):13-15.
[50]焦雄文,段颖.黄芪注射液对充血性心力衰竭左心室重构影响的临床研究.陕西中医学院学报[J].2006,29(3):19-20.
[5l]周智林,俞娉,林玎.黄芪注射液治疗充血性心力衰竭的疗效研究[J].中国中西药结合杂志,2001,21(10):747-749.
[52]严萍萍,张文芳,李勇,等.黄芪注射液对心力衰竭患者神经内分泌系统的影响.中华使用中西医杂志[J].2004,4(17):3188-3189.
[53]刘志高,熊正明,余细勇.黄芪注射液对充血性心力衰竭患者免疫功能的影响[J].中国中西医结合杂志[J].2003,23(5):351-353.
[54]柯晓,周宗梅,文明.黄芪注射液辅助治疗充血性心力衰竭的疗效及对免疫调节影响的观察[J].药学实践杂志,2004,22(5):268-269.
[55]卢威志,李玉光.黄燕注射液对心肌细胞缺氧献糖/复氧复糖损伤保护作用的实验研究[J].实用中西医结合杂志,1998.11(1):10-11.
[56]顾娟红,沈惟堂,李自普,等.黄芪对缺血大鼠心肌钙厦脂质过氧化物的影响[J].上海医科大学学报,1997,24(4):270-271.
[57]冯国清,秦晓晨,刘洁,等.黄芪对太鼠心肌罐血再灌注损伤的防护作用[J].中药药理与临床,1997,13(3):27-28.
[1]张子彬,Tsung O.Cheng,张玉传.充血性心力衰竭学[M].第1版.北京:科学技术文献出版社,2002:3-24,156-172,551-570.
[2]Ren(?)e Ventura-Clapier,Anne Garnier,Vladimir Veksler.Energy metabolism in heart failure[J].J Physiol,2004,555(Pt 1):1-13.
[3]Taegtmeyer H,Hems R,Krebs HA.Utilization of energy providing substrates in the isolated working rat heart[J].Biochem J,1980,186(3):701-711.
[4]Fujii N,Nozawa T,Igawa A,et al.Saturated glucose uptake capacity and impaired fatty acid oxidation in hypertensive hearts before development of heart failure[J].Am J Physiol Heart Circ Physiol,2004,287(2):H760-H766.
[5]de las Fuentes L,Herrero P,Peterson LR,et al.Myocardial Fatty Acid Metabolism:Independent Predictor of Left Ventricular Mass in Hypertensive Heart Disease[J].Hypertension,2003,41(1):83-87.
[6]Lopaschuk GD.Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure[J].Semin Cardiothorac Vasc Anesth,2006,10(3):228-230.
[7]Sack MN,Rader TA,Park,et al.Fatty acid oxidation enzyme gene expression is downregulated in the failing heart[J].Circulation,1996,94(11):2837-2842.
[8]Razeghi,P,Young,ME,Alcorn JL,et al.Metabolic gene expression in fetal and failing human heart[J].Circulation,2001,104(24):2923-2931.
[9]Pellieux C,Aasum E,Larsen TS,et al.Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway[J].J Mol Cell Cardiol,2006,41(3):459-466.
[10]殷仁富,陈金明.心脏能量学-代谢与治疗[M].第1版.上海:第二军医大学出版社,2002:151-181.
[11]Lionetti V,Linke A,Chandler MP,et al.Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure[J].Cardiovasc Res,2005,66(3):454-461.
[12]Rupp H,Rupp TP,Maisch B.Metabolism and the hypertrophied heart of the elderly[J].Dtsch Med Wochenschr,2005,130(12):726-730.
[13]Chen R,Liang F,Moriya J,et al.Peroxisome proliferator-activated receptors(PPARs) and their agonists for hypertension and heart failure:are the reagents beneficial or harmful?[J].Int J Cardiol,2008,130(2):131-139..
[14]Young ME,Laws FA,Goodwin OW,et al.Reactivation of peroxisome proliferator-activated receptor is associated with contratile with dysfunction in hypertrophied rat heart[J].J Biol ChEM,2001,276(48):44390-44395.
[15]Schupp M,Kintscher U,Fielitz J,et al.Cardiac PPARalpha expression in patients with dilated cardiomyopathy[J].Eur J Heart Fail,2006,8(3):290-294.
[16]Chen R,Liang F,Moriya J,et al.Peroxisome proliferator-activated receptors(PPARs) and their agonists for hypertension and heart failure:are the reagents beneficial or harmful?[J].Int J Cardiol,2008,130(2):131-139.
[17]Alibin CP,Kopilas MA,Anderson HD.Suppression of cardiac myocyte hypertrophy by conjugated linoleic acid:role of peroxisome proliferator-activated receptors alpha and gamma[J].J Biol Chem,2008,283(16):10707-10715.
[18]Faquan FQ,Wang F,Zhang SM,et al.Peroxisome proliferator activated receptor(PPAR)agonists inhibit hypertrophy of neonatal rat cardiac myocytes[J].Endocrinology,2003,144(9):4187-4194.
[19]胡琴,李隆贵,耿昭华.压力负荷性大鼠肥厚心肌过氧化物酶体增殖剂活化受体(PPARα)和卡尼汀棕榈酰转移酶(M-CPT-I)mRNA的表达变化[J].高血压杂志,2003,11(1):65-68.
[20]Orchard C,Kentish J.Effects of changes of pH on the contractile function of cardiac muscle[J].Am J Physiol,1990,258(6 Pt 1):C967-C981.
[21]Friehs I,Moran AM,Stamm C,et al.Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure[J].Circulation,1999,100(19 Suppl):Ⅱ187-Ⅱ193.
[22]Joost HG,Thorens B.The extended GLUT-family of sugar/polyol transport facilitators:nomenclature,sequence characteristics,and potential function of its novelmembers[J].MolMembrBiol,2001,18(4):247-256.
[23]Tian R,Musi N,Agostino J,et al.Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy[J].Circulation,2001,104(14):1664-1649.
[24]Abel ED,Kaulbach HC,Tian R,et al.Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart[J].J Clin Invest,1999,104(12):1703-1714.
[25]Liao R;Jain M;Cui L,et al.Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice[J].CirCulation.2002,106(16):2125-2131.
[26]McFalls EO,Murad B,Liow JS,et al.Glucose uptake and glycogen levels are increased in pig heart after repetitive ischemia[J].Am J Physiol Heart Circ Physiol,2002,282(1):205-211.
[27]杭 涛综述,江时森审校.葡萄糖转运子的表达和功能与心力衰竭的关系[J].医学研究生学报,2008,21(3):302-305.
[28]Ramasamy R,Hwang YC,Whang J,et al.Protection of ischemic heartsby high glucose ismediated,in part,by GLUT-4[J].Am J Physiol Heart Circ Physiol,2001,281(1):290-297.
[29]Tian R,Abel ED.Response of GLUT4-deficient hearts to ischemia under score the importance of glycolysis[J].Circulation,2001,103(24):2961-2966.
[30]Taegtmeyer H.Switching metabolic genes to build a better heart[J].Circulation,2002,106(16):2043-2045.
[31]苏静泽.黄芪组分对肥厚心肌能量代谢的干预作用及机制探讨[D].2008:10.
[32]Kakinuma Y,Miyauchi T,Yuki K,et al.Novel molecular mechanism of increased myocardial endothelin-1 expression in the failing heart involving the transcriptional factor hypoxia-inducible factor-lalpha induced for impaired myocardial energy metabolism[J].Circulation,2001,103(19):2387-2394.
[33]Zolk O,Solbach TF,Eschenhagen T,et al.Activation of negative regulators of the hypoxia-inducible factor(HIF) pathway in human end-stage heart failure[J].Biochem Biophys Res Commun,2008,376(2):315-320.
[34]Weidemann A,Klanke B,Wagner M,et al.Hypoxia,via stabilization of the hypoxia-inducible factor HIF-lalpha,is a direct and sufficient Stimulus for brain-type natriuretic peptide induction[J].Biochem J,2008,409(1):233-242.
[35]Huss JM,Kelly DP.Mitochondrial energy metabolism in heart failure:a question of balance[J].J Clin Invest,2005,115(3):547-555.
[36]Michell P.Keilin's respiratory chain concept and its chemiosmotic consequences[J].Science,1979,206(4423):1148-1159.
[37]Pallock M,Phaneuf S,Dirks A,et al.The role of apoptosis in the normal aging brain,skeletal muscle,and heart[J].Ann NY Acad Sci,2002,959:93-107.
[38]Moon CH,Jung YS,Kim MH,et al.Protein kinase C inhibitors attenuate protective effect of high glucose against hypoxic injury in H9c2 cardiac cells[J].Jpn J Physiol,2000,50(6):645-649.
[39]Kim MH,Jung YS,Moon CH,et al.High-glucose induced protective effect against hypoxic injury is associated with maintenance of mitochondrial membrane potential[J].Jpn J Physiol.2003,53(6):451-459.
[40]Sharma AK,Dhingra S,Khaper N,et al.Activation of apoptotic processes during transition from hypertrophy to heart failure in guinea pigs[J].Am J Physiol Heart Circ Physiol,2007,293(3):H1384-H1390.
[41]Lin L,Sharma VK,Sheu SS.Mechanisms of reduced mitochondrial Ca2+ accumulation in failing hamster heart[J].Pflugers Arch,2007,454(3):395-402.
[42]Hansson A,Hance N,Dufour E,et al.A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts[J].Proc Natl Acad Sci USA,2004,101(9):3136-3141.
[43]Quigley AF,Kapsa RM,Esmore D,et al.Mitochondrial respiratory chain activity in idiopathic dilated cardiomyopathy[J].J Card Fail.2000,6(1):47-55.
[44]陈丽芬.缺氧对大鼠脑线粒体氧化呼吸功能和ANT活性及异构体表达的影响[D].2004:44.
[45]Portman MA.The adenine nucleotide translocator:regulation and function during myocardial development and hypertrophy[J].Clin Exp Pharmacol Physiol,2002,29(4):334-338.
[46]Yamazaki N,Shinohara Y,Tanida K,et al.Structural properties of mammalian mitochondrial ADP/ATP carriers:identification of possible amino acids that determine functional differences in its isoforms[J].Mitochondrion,2002,1(4):371-379.
[47]Doerner A,Pauschinger M,Badoeff A,et al.Tissue-specific transcription pattern of the adenine nucleotide translocase isoforms in humans[J].FEBS Lett,1997,414(2):258-262.
[48]D(o|¨)rner A,Olesch M,Giessen S,et al.Transcription of the adenine nucleotide translocase isoforms in various types of tissues in the rat[J].Biochimicaet Biophysica Acta,1999,1417(1):16-24.
[48]李兵,柳君泽,陈丽芬.缺氧对大鼠心肌线粒体能量代谢和腺苷酸转位酶活性的影响[J].中国病理生理杂志,2006,22(3):460-463.
[50]李兵.缺氧过程中大鼠心肌线粒体能量代谢和腺苷酸转位酶活性及表达的研究[D].2004:30.
[51]伊木清,杨志勇,许葆华,等.游泳训练和硒缺乏对大鼠血清睾酮及心肌线粒体钙流入的影响[J].中国运动医学杂志,2000,19(4):353-355.
[52]Gunter TE,Buntinas L,Sparagna G,et al.Mitochondrial calcium transport:mechanisms and functions[J].Cell Calcium,2000,28(5-6):285-296.
[53]徐美英,马宇,王学敏,等.缺血再灌注损伤对兔心肌线粒体钙稳态的影响[J].2002,23(2):186-188.
[54]沈同,王镜岩.生物化学[M].第1版,北京:高等教育出版社,1991:17-18.
[55]Neubauer S,Horn M,Cramer M,et al.Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy[J].Circulation,1997,96(7):2190-2196.
[56]Beer M,Seyfarth T,Sandstede J,et al.Absolute concentrations of high-energy phosphate metabolites in normal,hypertrophied,and failing human myocardium measured noninvasively with(31)P-SLOOP magnetic resonance spectroscopy[J].J Am Coll Cardiol,2002,40(7):1267-1274.
[57]DU XH,Liang FY,Zhao XW.Effects of phosphocreatine on plasma brain natriuretic peptide level in elderly patients with chronic congestive heart failure[J].Nan Fang Yi Ke Da Xue Xue Bao,2009,29(1):154-155.
[58]沈炳权,陈明,朱霞,等.磷酸肌酸钠对慢性心衰患者心功能的影响[J].浙江中西医结合杂志,2008,18(1):15-16.
[59]Bessman SP,Geiger PJ.Transport of energy in muscle:the phosphorylcreatine shuttle[J],Science,1981,211(4481):448-452.
[60]Neubauer S,Frank M,Hu K,et al.Changes of creatine kinase gene expression in rat heart post-myocardial infarction[J].J Mol Cell Cardiol,1998,30(4):803-810.
[61]Ye Y,Wang C,Zhang J,et al.Myocardial creatine kinase kinetics and isoform expression in hearts with severe LV hypertrophy[J].Am J Physiol Heart Circ Physiol,2001, 281(1):H376-H386.
[62]Nascimben L,Ingwall JS,Pauletto P,et al.Creatine kinase system in failing and nonfailing human myocardium[J].Circulation,1996,94(8):1894-1901.
[63]Spindler M,Engelhardt S,Niebler R,et al.Alterations in the myocardial,creatine kinase system precede the development of contractile dysfunction in beta(1)-adrenergic receptor transgenic mice[J].J Mol Cell Cardiol,2003,35(4):389-397.
[64]Lygate CA,Fischer A,Sebag-Montefiore L,et al.The creatine kinase energy transport system in the failing mouse heart[J].J Mol Cell Cardiol,2007,42(6):1129-1136.
[65]Ye Y,Gong G,Ochiai K,et al.High-energy phosphate metabolism and creatine kinase in failing hearts:a new porcine model[J].Circulation,2001,103(11):1570-1576.
[66]Ventura-Clapier R,Kuznetsov AV,d'Albis A,et al.Muscle creatine kinase-deficient mice:alterations in myofibrillar function[J].J Biol Chem,1995,270(34):19914-19920.
[67]Dzeja PP,Vitkevicius KT,Redfield MM,et al.Adenylate kinase-catalyzed phosphotransfer in the myocardium:increased contribution in heart failure[J].Circulation Research,1999,84(10):1137-1143.
[68]农一兵,苏敬泽,温志浩,等.从补益心气与改善心肌能量代谢的关系探讨慢性心力衰竭中西医结合研究的思路[J].中医杂志,2007,48(11):1035-1036.
[69]廖家桢,林谦,于友华.心气虚证的中西医结合研究中药药理与临床研究进展(第四册,周金黄,王建华主编)[M].第1版.北京:军事医学科学出版社,1996:111-124.
[70]洪缨,许少珍,曾德源,等.黄芪注射液对慢性心衰大鼠心肌肥厚的逆转作用[J].中成药,2002,24(7):525-529.
[71]于忠学,关丽梅,王炎焱,等.复方黄芪无糖颗粒对心肌缺血能量代谢的影响[J].中医药信息,2003,20(1):55.
[1]薛振怀,黄伯梯,代早荣.黄芪注射液治疗充血性心力衰竭的临床观察[J].内蒙古中医药,2007,26(5):10-11
[2]李建辉,徐波,薛冀苏,等.硝普钠联合黄芪注射液治疗充血性心力衰竭的疗效观察[J].中国热带医学,2007,7(8):1343-1344
[3]王丽.黄芪注射液对肺心病心衰血清酶影响及疗效观察[J].实用中医内科杂志,2007,21(4):79-80
[4]吕培轩,郭清军.黄芪注射液治疗难治性心力衰竭30例疗效观察[J].哈尔滨医药,2007,27(4):21-22
[5]尚伟民,马敏芳.黄芪注射液治疗扩张型心肌病心力衰竭36例[J].中原医刊,2007,34(23):80
[6]杨勇娟.黄芪注射液结合西药治疗充血性心力衰竭的疗效观察[J].中外健康文摘·医药月刊,2007,4(11):31-32
[7]韦育林,李楚强,陈锡龙,等.黄芪注射液对充血性心力衰竭患者细胞因子和血管紧张素Ⅱ的影响[J].中国临床康复,2006,10(3):54-56
[8]张金国,高东升,谭洪勇,等.黄芪注射液对老年充血性心力衰竭患者血浆促炎性细胞因子的影响[J].济宁医学院学报,2006,29(2):13-15
[9]刘珠章.黄芪注射液治疗慢性心力衰竭对心输出量的影响[J].中华现代内科学杂志,2006,3(5):553-554
[10]黄建平.黄芪注射液治疗肺心病心衰40例临床观察[J].中国现代医药杂志,2006,8(9):25
[11]常健梅,王霞.卡维地洛配伍黄芪注射液治疗慢性心力衰竭25例疗效观察[J].陕西医学杂志,2006,35(5):601-602,609
[12]焦雄文,段颖.黄芪注射液对充血性心力衰竭左心室重构影响的临床研究[J].陕西中医学院学报2006,29(3):19-20
[13]李玉侠.黄芪注射液治疗老年慢性心力衰竭疗效观察[J].基层医学论坛(B版),2006,10(5):419-420
[14]杨水娥,彭爱英,李红燕.黄芪注射液治疗慢性心力衰竭疗效的研究[J].中华实用中西医杂志,2006,19(10):1111,1113
[15]郭辉,陈红伟.黄芪注射液治疗慢性充血性心力衰竭42例[J].中原医刊,2006,33(2):85-86
[16]陆振涛,赵大国,刘勇.黄芪注射液治疗冠心病心力衰竭的临床观察[J].基层医学论坛(B版),2006,10(1):1-2
[17]王恒和.黄芪注射液辅助治疗难治性心力衰竭临床研究[J].中国中医急症,2005,14(11):1070-1071
[18]曾健球,郭秀春,汪锦丹,等.黄芪注射液治疗充血性心力衰竭36例[J].河南中医,2005,25(11):71
[19]高建辉.黄芪注射液治疗充血性心力衰竭临床观察[J].广东药学院学报,2005,21(5):610-611
[20]马玲,余俊丽,韩月锋.黄芪注射液治疗肺原性心脏病顽固性心力衰竭临床观察[J].河南中医,2005,25(10):78-79
[21]席周让,金晓琴.黄芪注射液治疗充血性心力衰竭的疗效观察[J].现代医药卫生,2005,21(17):2337-2338
[22]胡小松,王晓娟.黄芪注射液治疗充血性心力衰竭临床观察[J].现代医药卫生,2005,21(17):2333-2334
[23]过海东,刘龙华,元文峰,等.黄芪注射液治疗慢性肺心病合并心衰的疗效观察[J].实用中西医结合临床,2005,5(4):22
[24]郭宝云.黄芪注射液治疗充血性心力衰竭65例疗效观察[J].新疆医科大学学报,2005,28(7):662-663
[25]罗康华,陈实亭.黄芪注射液对慢性充血性心力衰竭左心功能的影响[J].中原医刊,2005,32(10):52
[26]张金国,杨娜,何华,等.黄芪注射液对慢性心力衰竭患者血浆凋亡相关因子的影响[J].中国中西医结合杂志,2005,25(5):400-403
[27]刘有才.黄芪注射液治疗老年心力衰竭疗效观察[J].新乡医学院学报,2005,22(3):244-245
[28]刘英芹,李芸.黄芪注射液治疗充血性心力衰竭临床研究[J].实用中医药杂志,2005,21(4):198-199
[29]吴新华,陈康文.黄芪注射液治疗扩张型心肌病心力衰竭26例疗效观察[J].云南中医中药杂志,2005,26(1):13
[30]董青,吴先旺,张敬芳.黄芪注射液治疗充血性心力衰竭61例疗效观察[J].现代医药卫生,2005,8(3):285-286
[31]刘爱好.黄芪注射液治疗慢性充血性心力衰竭临床观察[J].浙江中西医结合杂志,2005,15(1):32-33
[32]李敏慧,彭景拾.黄芪注射液治疗慢性肺心病心力衰竭疗效观察[J].医药论坛杂志,2004,25(24):57
[33]张晋生.黄芪注射液治疗充血性心力衰竭疗效观察[J].实用医技杂志,2004,11(12A):2617
[34]李靖.黄芪注射液治疗充血性心力衰竭的疗效观察[J].华北煤炭医学院学报,2004,6(6):746
[35]柯晓,周宗梅,文明,等.黄芪注射液辅助治疗充血性心力衰竭的疗效及对免疫调节影响的观察[J].药学实践杂志,2004,22(5):268-270
[36]刘彩红,李英华.黄芪注射液治疗充血性心力衰竭临床观察[J].辽宁中医学院学报,2004,6(5):390
[37]严萍萍,张文芳,李勇,等.黄芪注射液对心力衰竭患者神经内分泌系统的影响[J].中华实用中西医杂志,2004,17(21):3188-3190
[38]吴莉雯.黄芪注射液治疗慢性肺心病心力衰竭的疗效观察[J].新疆医学,2004,34(4):107-108
[39]张少峰,王廷会,黄芪注射液治疗慢性充血性心力衰竭49例[J].临床心血管病杂志,2004,20(8):496
[40]侯桂萍.黄芪注射液联合硝酸甘油治疗充血性心力衰竭[J].中华中西医临床杂志,2004,4(7):879
[41]程杭,贾连旺.黄芪注射液治疗老年退行性心脏瓣膜病心功能不全[J].浙江中西医结合杂志,2004,14(6):347-348
[42]罗庆东,王艳霞,胡敏.黄芪注射液配合常规疗法治疗老年慢性充血性心力衰竭46例疗效观察[J].黑龙江中医药,2004,(3):8-9
[43]祝星,叶红华,王胜煌,等.黄芪注射液治疗难治性心力衰竭疗效观察[J].浙江中西医结合杂志,2004,14(5):268-270
[44]张玉伟.黄芪注射液治疗重症充血性心力衰竭的疗效观察[J].中华现代中西医杂志,2004,2(4):311-312
[45]谭敏豪,范金让.地奥黄芪注射液治疗心力衰竭疗效观察[J].中华临床医学研究杂志,2004,10(89):1092-1093
[46]尹乐安.黄芪注射液对肺心病心力衰竭心功能的影响:附102例报告[J].中国医师杂志,2004,6(3):427
[47]原广平.黄芪注射液治疗慢性心力衰竭的临床疗效评价[J].中国临床药靼学与治疗学,2003,8(6):710-711
[48]李书瑞,郝建峰,武付忠,等.不同剂量黄芪注射液治疗充血性心力衰竭临床疗效观察[J].中华实用中西医杂志,2003,16(12):1665-1667
[49]顾旭,尚树忠,郭锐.黄芪注射液辅助治疗充血性心力衰竭68例[J].医药导报,2003,22(8):556-557
[50]房泽岱,秦元玲.黄芪注射液治疗充血性心力衰竭的临床观察[J].中原医刊,2003,30(14):6-7
[51]蔡静,李雪萍,陈鹏.黄芪注射液治疗肺心病并心衰56例疗效观察[J].中华医学写作杂志,2003,10(12):1097-1098
[52]刘芬,付兰慧.黄芪注射液治疗充血性心力衰竭[J].临床荟萃,2003,18(11):639
[53]王希宁.美托洛尔联用黄芪注射液治疗缺血性心脏病心力衰竭35例临床碑察[J].湖南中医药导报,2003,9(5):15-17
[54]孙晓鸣.黄芪注射液治疗肺原性心脏病心力衰竭40例疗效观察[J].齐齐哈尔医学院学报,2003,24(5):520
[55]刘志高,熊正明,余细勇.黄芪注射液对充血性心力衰竭患者免疫功能的影响[J].中国中西医结合杂志,2003,23(5):351-353
[56]曾和松,吴正贤,刘正湘,等.黄芪注射液治疗心功能不全并心律失常的临床观察[J].实用心脑肺血管病杂志,2003,11(2):70-72
[57]智宏民,史晓婧.黄芪注射液治疗老年心力衰竭疗效观察[J].临床医学,2003, 23(4):54-55
[58]邢鹏云,贾连旺.黄芪注射液辅助治疗充血性心力衰竭的疗效分析[J].心血管康复医学杂志,2003,12(1):82-83
[59]罗贤初.黄芪注射液治疗充血性心力衰竭30例临床观察[J].中国中医急症,2003,12(1):35
[60]王红梅,高晟.黄芪注射液治疗老年充血性心力衰竭[J].天津中医,2002,19(6):21
[61]李长泉,朱小霞.黄芪注射液辅助治疗慢性充血性心力衰竭疗效观察[J].医学理论与实践,2002,15(11):1277-1278
[62]周宗梅,蔡爱玲,罗昌雄,等.黄芪注射液辅助治疗冠心病心力衰竭的临床观察[J].湖北中医杂志,2002,24(9):11-12
[63]朱春玲,彭红英.黄芪注射液在慢性肾功能衰竭尿毒症合并心力衰竭治疗中的应用[J].贵州医药,2002,26(8):762
[64]王莉,陈铁梅.黄芪注射液治疗右心衰竭64例疗效观察[J].齐齐哈尔医学院学报,2002,23(6):621
[65]许国星,孙丽娟.黄芪注射液治疗肺心病并发心衰疗效观察[J].济宁医学院学报,2002,25(2):65
[66]蔺翠兰,王红,史慧玲.黄芪注射液辅助治疗肺心病心力衰竭58例[J].中医药学报,2002,30(3):15
[67]孙洪.黄芪注射液治疗慢性心功能不全40例疗效观察[J].中国中医药科技,2002,9(3):187
[68]尹绢,魏群.黄芪注射液治疗肺原性心脏病心力衰竭疗效观察[J].河北中医,2002,24(4):308-309
[69]章大进.黄芪注射液治疗肺心病心衰42例疗效观察[J].现代中西医结合杂志,2002,11(5):408
[70]闫惠珍,闫晓婷.黄芪注射液治疗肺心病心力衰竭80例[J].中国康复,2002,17(2):112
[71]陈启华,黄芪注射液伍用钾镁液治疗心衰疗效观察[J].心血管康复医学杂志,2001,10(6):554-555
[72]尚玉红,肖艳.黄芪注射液治疗充血性心力衰竭的临床研究[J].河南中医药学刊,2001,16(6):32-33
[73]周智林,俞娉,林玎,等.黄芪注射液治疗充血性心力衰竭的疗效研究[J].中国中西医结合杂志,2001,21(10):747-749
[74]马战平,程小红,王凌.黄芪注射液辅佐治疗慢性肺心病心衰86例[J].陕西中医,2001,22(10):579-580
[75]原广平.黄芪注射液治疗慢性心力衰竭的疗效观察.[J],中国医院药学杂志,2001,21(9S):85
[76]张虎.黄芪注射液佐治肺心病心力衰竭66例[J].中国中西医结合急救杂志,2001,8(5):313
[77]卢延生.不同剂量黄芪注射液治疗心衰疗效对比[J].江苏中医,2001,22(9):45
[78]潘国良,马卫琴.黄芪注射液治疗肺原性心脏病并心力衰竭[J].浙江中西医结合杂志,2001,11(8):496-497
[79]李伟,赵卫.黄芪注射液治疗慢性充血性心力衰竭50例临床观察[J].浙江中西医结合杂志,2001,11(5):307-308
[80]胡锦章,甘结友.黄芪注射液治疗慢性心衰30例[J].中国临床药理学与治疗学,2001,6(1):78
[81]林宏初,吴恒莲,阮雪玲.黄芪注射液治疗慢性肾衰竭合并心力衰竭的临床疗效[J].中国中西医结合肾病杂志,2000,1(4):218-220
[82]褚瑰翔,彭新念.黄芪注射液辅助治疗难治性心力衰竭[J].湖北中医杂志,2000,22(10):29-30
[83]高旭.黄芪注射液对充血性心力衰竭患者心功能及血液流变学的影响[J].中国临床药理学与治疗学杂志,2000,5(3):257-258
[84]王健,盛净,陈元美,等.生脉注射液和黄芪注射液对冠心病心功能不全患者舒张功能的影响[J].中国综合临床,2000,16(9):702-703
[85]邓桂银,周素清,李晓光.黄芪注射液治疗难治性心力衰竭30例[J].中国药业,2000,9(8):30
[86]杨继荣,谢其中.黄芪注射液治疗慢性心功能不全疗效观察[J].现代中西医结合杂志,2000,9(12):1131
[87]钱海凌,黄立武.大剂量黄芪注射液治疗难治性心衰的临床观察[J].辽宁中医杂志,2000,27(5):202-203
[88]张力军,王桂霞,张关生.黄芪注射液佐治肺心病心衰疗效观察[J].西藏医药杂志,2000,21(2):14-15
[89]王俐.黄芪注射液与硝酸甘油合用治疗心衰疗效观察[J].重庆医学,2000,29(1):71-72
[90]何居仁,马丹军.黄芪注射液治疗充血性心力衰竭作用机理探讨[J].上海医药,2000,21(1):25-26
[91]曾群英.黄芪注射液治疗重症充血性心力衰竭的疗效研究[J].中药药理与临床,1999,15(6):36-38
[92]包祥宁.黄芪注射液治疗老年充血性心衰[J].中药药理与临床,1999,15(6):39-40
[93]文旺秀,严夏,吴焕林.黄芪注射液治疗慢性心力衰竭的疗效观察[J].中药药理与临床,1999,15(6):38-39
[94]钱嘉宏.大剂量黄芪注射液治疗充血性心力衰竭的疗效观察[J].江苏临床医学杂志,1999,3(6):545-546
[95]周波,张小燕,常中凡,等.黄芪注射液辅助治疗肺心病心力衰竭64例[J].中国新药与临床杂志,1999,18(6):374-375
[96]王兵,陈康乐,邓世周,等.常规疗法加黄芪注射液治疗肺心病并心衰及呼衰51例观察[J].实用中医药杂志,1999,15(10):21-22
[97]王世茹,李吉荣,段国威.黄芪注射液用于妊高征性心脏病、心功能不全的疗效观察[J].临床荟萃,1999,14(S):241
[98]高金柱.黄芪注射液治疗心力衰竭的临床观察[J].临床荟萃,1999,14(S):242
[99]孙跃东,杨丽华.比较黄芪注射液和心先安对充血性心力衰竭的疗效[J].临床荟萃,1999,14(S):235-236
[100]崔伟,刘敬友.黄芪注射液治疗冠心病心功能不全疗效观察[J].实用中西医结合杂志,1998,11(10):896
[101]孙琼,张宝陵,孙立勤.黄芪注射液治疗肺心病心衰42例[J].中国中医急症,1998,7(5):206
[102]杨秀丽,张朝霞.地奥黄芪注射液辅助治疗扩张型心肌病充血性心力衰竭疗效观察[J].临床医学,1998,18(9):38
[103]杨忠奇,刘明平.黄芪注射液在治疗充血性心力衰竭时对洋地黄中毒发生率的影响[J].中药新药与临床药理,1998,9(2):80-81
[104]李绍敏,汪小红.黄芪注射液治疗严重充血性心力衰竭疗效及其对QT离散度的影响[J].中西医结合实用临床急救,1998,5(3):123-125
[105]王东红.黄芪注射液治疗慢性肺心病心衰73例[J].江苏中医,1998,19(3):18-19
[106]赵智深,刘福喜,杨留振.黄芪注射液辅助治疗充血性心力衰竭.[J],实用中西医结合杂志,1998,11(1):26
[107]张兴家,范丽华,张世英,等.黄芪注射液治疗慢性肾功能不全并心力衰竭临床研究[J].长春中医学院学报,1997,13(4):18
[108]田浪,艾俊,邓成明.黄芪注射液与巯甲丙脯酸联用治疗难治性慢性肺原性心衰46例临床观察.[J],上海医药,1997,(11):16
[109]杨芝芸.黄芪注射液治疗高原肺心病心衰65例[J].辽宁中医杂志,1997,24(6):261
[110]李绍敏,吕美农.黄芪注射液配合治疗肺心病心衰30例[J].安徽中医学院学报,1997,16(2):19-20
[111]李黔云,吴洋.黄芪注射液治疗慢性心衰68例疗效观察[J].上海医药,1997,(1):19
[112]田凤军,陈亚丽,何秀月,等.黄芪注射液治疗肺心病心力衰竭疗效观察[J].河北中西医结合杂志,1997,6(1):45-46
[113]翟理黄,王梅,岳金明,等.黄芪注射液治疗充血性心力衰竭的临床观察[J].上海医药,1995,(11):10-12
[114]杨鑫.黄芪注射液治疗老年人难治性心力衰竭的临床研究[J].齐齐哈尔医学院学报,2008,29(12):1464
[115]惠树林,郝文辉.黄芪注射液治疗慢性肺源性心脏病心力衰竭疗效观察[J].现代中西医结合杂志,2008,17(13):1965
[116]吕俊.西药联合黄芪注射液治疗慢性充血性心力衰竭36例观察[J].实用中医药杂志,2008,24(3):164-165
[117]孟捍华,马敏杰.黄芪注射液对慢性充血性心力衰竭治疗作用的观察[J].中医药临床杂志,2008,20(1):40-41
[118]林果为,沈富民.现代临床流行病学[M].上海:复旦大学出版社,2000.
[119]Cowie MR,Wood DA,Coats AJS,et al.Survival of patients with a new diagnosis of heart failure:a population based study[J].Heart,2000,83(5):505-510.
[120]鄢立新,唐卫文,付铁军,等 不同厂家产黄芪注射液中黄芪甲苷的含量考察[J].中成药,2004,26(8):626-628.
[121]吴晓放,高日胜,许文年,等.黄芪注射液与4种输液的配伍实验[J].2000,18(6):374-376.
[122]王家良.临床治疗性研究的设计与评价[J].中华医学杂志,1999,79(2):94-96.
[123]刘建平.循证医学方法与中医疗效评价[J].首都医科大学学报,2007,28(2):212-215.
[124]Curtis JP,Sokol SI,Wang Y,et al.The association of left ventricular ejection fraction,mortality,and cause of death in stable outpatients with heart failure[J].J Am Coll Cardiol,2003,42(4):736-742.
[125]Koyama Y,Takeishi Y,Arimoto T,et al.High serum level of pentosidine,an advanced glycation end product(AGE),is a risk factor of patients with heart failure[J].J Card Fail,2007,13(3):199-206.
[126]王新房.超声心动图学[M].北京:人民卫生出版社:278-281.
[127]苏国研.中药临床疗效评价标准的思考[J].国际医药卫生导报,2003,2:119-120.
[128]于嘉,谢雁鸣.中医卫生经济学评价的研究思路与方法[J].中国中医药信息杂志,13(6):106-108.
[129]Dokainish H.Combining tissue Doppler echocardiography and B-type natriuretic peptide in the evaluation of left ventricular filling pressures:review of the literature and clinical recommendations[J].Can J Cardiol,2007,23(12):983-989.
[130]张宏伟,唐金陵,刘建平.临床试验中的对照设置[J].中医杂志,2007,48(2):125-128.
[131]魏莉,苏振军,关富山.黄芪注射液治疗小儿脑瘫的随机、双盲临床研究[J].2008,6(3):234-236.
[132]刘鸣,张世洪.新知识:临床试验中的意向处理分析[J].英国医学杂志:中文版,2001,4(4):223-224.
[133]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095.
[1]林谦,农一兵,黄启福.从心肌能量代谢探讨慢性心力衰竭心气虚证的实质[J].北京中医药大学学报,2007,7(7):445-446,474.
[2]苏敬泽,林谦,农一兵.黄芪组分配伍对血管紧张素Ⅱ致肥大心肌细胞模型线粒体活力的影响[J].2007,26(11):742-744.
[3]殷仁富,陈金明.心脏能量学-代谢与治疗[M].第1版.上海:第二军医大学出版社,2002:151-183.75.177.
[4]Harary I,Farkey B.In vitro studies of single isolated beating heart cell[J].Science,1960,131:1674-1675.
[5]H(u|¨)gel S,Horn M,de Groot M,et al.Effects of ACEInhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction[J].Am J Physiol,1999,277(6 Pt 2):H2167-H2175.
[6]Hammerschmidt S,Bell M,B(u|¨)chler N,et al.Acute changes of myocardial creatine kinase gene expression under β-adrenergic stimulation[J].Biochim Biophys Acta,,2000,1502(3):471-480.
[7]李兵.缺氧过程中大鼠心肌线粒体能量代谢和腺苷酸转位酶活性及表达的研究.[D],2004:12.30.
[8]Rosamond W,Flegal K,Furie K,et al.Heart disease and stroke statistics-2008 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J].Circulation,2008,117(4):e25-e 146.
[9]Holubarsch CJ,Rohrbach M,Karrasch M,et al.A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure:the ERGO(etomoxir for the recovery of glucose oxidation) study[J].Clin Sci(Lond),2007,113(4) 205-212.
[10]赵耐久,张玉东.血管紧张素Ⅱ受体拮抗剂与心力衰竭患者心室重塑的研究进展[J].中华现代临床医学杂志,2005,3(11):1041-1042.
[11]Lijnen P,Petrov V.Renin-angiotensin system,hypertrophy and gene expression in cardiac myocytes[J].J Mol Cell Cardiol,1999,31(5):949-970.
[12]Mathur A,.Hong Y,Kemp BK,et al.Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes[J].Cardiovasc Res,2000,46(1):126-138.
[13]Sharma AK,Dhingra S,Khaper N,et al.Activation of apoptotic processes during transition from hypertrophy to heart failure in guinea pigs[J].Am J Physiol Heart Circ Physiol,2007,293(3):H1384-H1390.
[14]Choudhary R;Baker KM,Pan J.All-trans retinoic acid prevents angiotensin Ⅱ- and mechanical stretch-induced reactive oxygen species generation and cardiomyocyte apoptosis[J].J Cell Physiol,2008,215(1):172-181.
[15]陈丽芬.缺氧对大鼠脑线粒体氧化呼吸功能和ANT活性及异构体表达的影响[D].2004:44.
[16]Portman MA.The adenine nucleotide translocator:regulation and function during myocardial development and hypertroph[J].Clin Exp Pharmacoi Physiol,2002,29(4):334-338.
[17]D(o|¨)rner A,Olesch M,Giessen S,et al.Transcription of the adenine nucleotide translocase isoforms in various types of tissues in the rat[J].Biochimicaet Biophysica Acta,1999,1417(1):16-24.
[18]李兵,柳君泽,陈丽芬.缺氧对大鼠心肌线粒体能量代谢和腺苷酸转位酶活性的影响[J].中国病理生理杂志,2006,22(3):460-463.
[19]Hammerschmidt S,Bell M,B(u|¨)chler N,et al.Acute changes of myocardial creatine kinase gene expression under beta-adrenergic stimulation[J].Biochim Biophys Acta,2000,1502(3):471-480.
[20]De Sousa E,Veksler V,Minajeva A,et al.Subcellular creatine kinase alterations.Implications in heart failure[J].Circ Res,1999,85(1):68-76.
[21]Saupe KW,Spindler M,Hopkins JC,et al.Kinetic,thermodynamic,and developmental consequences of deleting creatine kinase isoenzymes from the heart.Reaction kinetics of the creatine kinase isoenzymes in the intact heart[J].J Biol Chem,2000,275(26):19742-19746.
[22]Lygate CA,Fischer A,Sebag-Montefiore L,et al.The creatine kinase energy transport system in the failing mouse heart[J],J Mol Cell Cardiol,2007,42(6):1129-1136.
[23]Neubauer S,Frank M,Hu K,et al.Changes of creatine kinase gene expression in rat heart post-myocardial infarction[J].J Mol Cell Cardiol,1998,30(4):803-810.
[24]Hoang CD,Zhang J,Payne RM,et al.Post-infarction left ventricular remodeling induces changes in creatine kinase mRNA and protein subunit levels in porcine myocardium[J].Am J Pathol,1997,151(1):257-264.
[25]管佳,毕志明,李萍.黄芪皂苷注射液指纹图谱的研究[J].中国中药杂志,2006,31(10):807-809.
[2]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095.
[3]Task Force Members,Kenneth Dickstein,Alain Cohen-Solal,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine(ESICM)[J].Eur.Heart J,2008,29(19):2388-2442.
[4]McKee PA,Castelli WP,McNamara PM,et al.The natural history of congestive heart failure:the Framingham study[J].N Engl J Med,1971,285(26):1441-1446.
[5]张子彬,Tsung O.Cheng,张玉传.充血性心力衰竭学[M].第1版.北京:科学技术文献出版社,2002:223-224.
[6]胡大一.心力衰竭诊断进展[EB/OL].http://pkuph.365heart.com/html/11663.shtm-1,2006-03-08/2009-02-20.
[7]Pennell DJ,Sechtem UP Higgins CB,et al.Clinical indications for cardiovascular magnetic resonance(CMR):Consensus Panel report[J].J Cardiovasc Magn Reson,2004,6(4):727-765.
[8]Hendel RC,Patel MR,Kramer CM,et al.ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging:a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group,American College of Radiology,Society of Cardiovascular Computed Tomography,Society for Cardiovascular Magnetic Resonance,American Society of Nuclear Cardiology,North American Society for Cardiac Imaging,Society for Cardiovascular Angiography and Interventions,and Society of Interventional Radiology[J].J Am Coll Cardiol,2006,48(7):1475-1497.
[9]朱文玲.心力衰竭的进展-心力衰竭的临床和影像学诊断[J].中国循环杂志,2006,21(1):2.
[10]Roul G,Moulichon ME,Bareiss P,et al.Exercise peak VO_2 in chronic heart failure:is it still of value?[J].Eur Heart J,1994,15(4):495-502.
[11]Morales FJ,Montemayor T,Martinez A.Shuttle versus six-minute walk test in the prediction of outcome in chronic heart failure[J].Int J Cardiol,2000,76(2-3):101-105.
[12]Bittner V,Weiner DH,Yusuf S,et al.Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction[J].JAMA,1993,270(14):1702-1707.
[13]Roul G,Germain P,Bareiss P,et al.Does the 6-minute walk test predictsthe prognosis in patients with NYHA class Ⅱ or Ⅲ chronic heart failure[J].Am Heart J,1998,136(3):139-457.
[14]Troosters T,Gosselink R,Decramer M.Six minute walking distance in healthy elderly subjects[J].Eur Respir J,1999,14(2):270-274.
[15]王新房.超声心动图学[M].第3版.北京:人民卫生出版社,1999:278-281.
[16]Nikitin NP,Loh PH,Silva R,et al.Prognostic value of systolic mitral annular velocity measured with Doppler tissue imaging in patients with chronic heart failure caused by left ventricular systolic dysfunction[J].Heart,2006,92(6):775-779.
[17]Sudoh T,Kangwa K,Minamion N,et al.A new natriuretic peptide in porcine brain[J].Nature,1988,332(6159):78.
[18]尹欣,吴春旭,徐丹丹.血浆脑钠素水平与心衰患者左心功能关系的临床研究[J].标记免疫分析与临床,2005,12(2):76-77,81.
[19]卢敏,张梦玺,曹军香.心力衰竭患者脑钠肽、C反应蛋白与心功能的关系[J].实用医学杂志,2007,23(5):658-660.
[20]Maisel AS,Koon J,Krishnaswamy P,et al.Utility of B-natriuretic pepetide as a rapid,point-of care test foscreening patients undergoing echocardiography todetermine left ventricular dysfunction[J].Am Heart J,2001,141(3):367-3741
[21]Maisel AS,Krishnaswamy P,Nowak RM,et al.Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J].N Engl J Med,2002,347(3):161-167.
[22]Dao Q,Krishnaswamy P,Kazanegra R,et al.Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting[J].J Am Coll Carol,2001,37(2):379-385.
[23]Richards AM,Nicholls MG,Espiner EA,et al.B-type natriuretic peptide and ejection fraction for prognosis after myocardial infarction[J].Circulartion,2003,107(22):2786-2792.
[24]Bettencourt P,Ferreira A,Dias P,et al.Evaluation of brain natriuretic peptide in the diagnosis of heart failure[J].Cardiology,2000,93(1):19-25.
[25]Suzuki T,Yamaoki K,Nakajima O,et al.Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic;peptide levels[J].Jpn Heart J,2000,41(2):205-214.
[26]Nielsen OW,McDonagh TA,Robb SD,et al.Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population[J].J Am Coll Cardiol,2003,41(1):113-120.
[27]Maisel A.B-type natriuretic peptide levels:diagnostic and prognostic in congestive heart failure:what's next?[J].Circulation,2002,105(20):2392-2397.
[28]Marantz PR,Tobin JN,Wassertheil-Smoller S,et at.The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria[J].Circulation,1988,77(3):607-612.
[29]吴学思.心力衰竭的进展-慢性心力衰竭的主要进展概述-半个世纪的变迁[J].中国循环杂志,2005,20(5):323-324.
[30]The CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure.Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)[J].N Engl J Med,1987,316(23):1429-1435.
[31]The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure[J].N Engl J Med,1991,325(5):293-302.
[32]Cohn JN,Johnson G,Ziesche S,et al,A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure[J].N Engl J Med,1991,325(5):303-310.
[33]The SOLVD Investigators.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions[J].N Engl J Med,1992,327(10):685-691.
[34]McAlister FA,Stewart S,Ferrua S,et al.Multidisciplinary strategies for the management of heart failure patients at high risk for admissions systematic review of randomized trials[J].J Am Coll Cardiol,2004,44(4):810-819.
[35]Majumdar SR,McAlister FA,Cree M,et al.Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS)study [J].Clin Ther.2004,26(5):694-703.
[36]Cohn JN,Tognoni G.A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure[J].N Engl J Med,2001,345(23):1667-1675.
[37]McMurray JJ,Ostergren J,Swedberg K,et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-c-onverting-enzyme inhibitors:the CHARM-Added trial[J].Lancet,2003,362(9386):767-771.
[38]Pitt B,Segal R,Martinez FA,et al.Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study,ELITE)[J].Lancet,1997,349(9054):747-752.
[39]McKelvie RS,Yusuf S,Pericak D,et al.Comparison of candesartan,enalapril,and their combination in congestive heart failure:randomized evaluation of strategies for left ventricular dysfunction (RESOLVD)pilot study[J].Circulation,1999,100(10):1056-64.
[40]Pitt B,Poole-Wilson PA,Segal R,et al.Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomised trial-the Losartan Heart Failure Survival Study ELITE Ⅱ[J].Lancet,2000 355(9215):1582-1587.
[41]Dickstein K,Kjekshus J.OPTIMAAL Steering Committee of the OPTIMAAL Study Group,Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial.Optimal Trial in Myocardial Infarction with Angiotensin Ⅱ Antagonist Losartan[J].Lancet,2002,360(9335):752-760.
[42]Velazquez EJ,Pfeffer MA,McMurray JV,et al.Valsartan in acute myocardial infarction (VALIANT)trial:baseline characteristics in context[J].Eur J Heart Fail,2003,5(4):537-544.
[43]Bohm M,Baumhakel M,Probstfield JL,et al.Sexual function,satisfaction,and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients:substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND)[J].Am Heart J,2007,154(1):94-101.
[44]Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])[J].Am J Cardiol,1996,78(8):902-907.
[45]Pitt B,Zannad F,Remme WJ,et al.The effect of spironolactone on morbidity and mortality in parients with severe heart failure.For the RALEA Ivestigator[J].N Engl Med,1999,341(10):709-717
[46]Waagstein F,Bristow MR,Swedberg K,et al.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.Metoprolol in Dilated Cardiomyopathy (MDC)Trial Study Group[J].Lancet,1993,342(8885):1441-1446.
[47]CIBIS Investigators and Committees.A randomized trial of beta-blockade in heart failure.The Cardiac Insufficiency Bisoprolol Study (CIBIS)[J].Circulation,1994,90(4):1765-73.
[48]Colucci WS,Packer M,Bristow MR,et al.Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure.US Carvedilol Heart Failure Study Group[J].Circulation,1996,94(11):2800-2806.
[49]Packer M,Fowler MB,Roecker EB,et al.Effect of carvedilol on the morbidity of patients with severe chronic heart failure:results of the carvedilol prospective randomized cumulative survival (COPERNICUS)study[J].Circulation,2002,106(17):2194-2199.
[50]Hjalmarson A,Goldstein S,Fagerberg B,et al.Effects of controlled-release metoprolol on total mortality,hospitalizations,and well-being in patients with heart failure:the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF).MERIT-HF Study Group[J].JAMA,2000,283(10):1295-1302.
[51]CIBIS-Ⅱ investigator and committees.The Cardiac Insufficiency Bisoprolol Study Ⅱ (CIBIS-Ⅱ):a randomised trial[J].Lancet,1999,353(9146):9-13.
[52]Flather MD,Shibata MC,Coats AJS,et al.Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)[J].Eur Heart J,2005,26(3):215-225.
[53]Willenheimer R,van Veldhuisen DJ,Silke B,et al.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBTS)Ⅲ[J].Circulation,2005,12(16):2426-2435.
[54]Uretsky BF,Young JB,Shahidi FE,et al.Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure:results of the PROVED trial.PROVED Investigative Group[J].J Am Coll Cardiol,1993,22(4):955-962.
[55]Packer M,Gheorghiade M,Young JB,et al.Withdrawal of digox-in from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors:RADIANCE Study[J].N Enel J Med,1993,329(1):l-7.
[56]The Digitalis Investigation Group.The effect of digoxin on mortality and morbidity in patients with heart failure[J].N Engl J Med,1997,336(8):525-533.
[57]Ahmed A,Rich MW,Love TE,et al.Digoxin and reduction in mortality and hospitalization in heart failure:a comprehensive post hoc analysis of the DIG trial[J].Eur Heart J,2006,27(2):178-186.
[58]Neuberg GW,Miller AB,O'Connor CM,et al.Diuretic resistance predicts mortality in patients with advanced heart failure[J].Am Heart J,2002,144(1):31-38.
[59]Sakai S,Mivauchi T,Kebayashi M,et al.Inhibition of myocardial endothelin pathway improves long-term survival in heart failures[J].Nature,1996,384(6607):353-355.
[60]Torre-Amione G,Young JB,Durand J,et al.Hemodynamic effects of tezosentan,an intravenous dual endothelin receptor antagonist,in patients with class Ⅲ to IV congestive heart failure[J].Circulation,2001,103(7):973-980.
[61]Schalcher C,Cotter G,Reisin L,et al.The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failures [J].Am Heart J,2001,142(2):340-349.
[62]GuillermoTA,JamesB,Wilson S,et al.Hemodynamic and clinical effects of tezosentan,an intravenous dual endothelin receptor antagonist,in patients hospitalized for acute decompensated heart failure[J].J Am Coll Cardiol,2003,42(1):140-147.
[63]Cowburn PJ,Cleland JG,McArthur JC,et al.Short-term haemodynamic effects of BQ-123,a selective endothelin ET(A)-receptor antagonist,in chronic heart failure[J].Lancet,1998,352(9123):201-202.
[64]Kim NN,Dhir V,Azadzoi KM,et al.Pilot study of the endothelin-A receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction[J].J Androl,2002,23(1):76-83.
[65]Spieker LE,Mitrovic V,Noll G,et al.Acute hemodynamic and neurohumoral effects of selective ET(A)receptor blockade in patients with congestive heart failure.ET 003 Investigators[J].J Am Coll Cardiol,2000,35(7):1745-1752.
[66]Poole-Wilson P,Colucci N,Massie B,et al.Heart Failure:Scientific Principles and Clinical Practice[M].New York:Churchill Livingstone,1997:155-171.
[67]许顶立,任吴,充血性心力衰竭水潴留的机制—Aquaporin2水通道蛋白的作用,[J],2000,31(2)：150-152．
[68]Recio-Mayoral A,Kaski JC,McMurray JJ,et al.Clinical trials update from the European Society of Cardiology Congress in Vienna,2007:PROSPECT,EVEREST,ARISE,ALOFT,FINESSE,Prague-8,CARESS in MI and ACUITY[J].Cardiovasc Drugs Ther,2007,21(6):459-465.
[69]Keating GM,Goa KL.Nesiritide:a review of its use in acute decompensated heart failure[J].Drugs,2003,63(1):47.
[70]Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF).Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial[J].JAMA,2002,287(12):1531-1540.
[71]Yancy CW,Saltzberg MT,Berkowitz RL,et al,Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial)[J].Am J Cardiol 2004,94(5):595-601.
[72]Peacock WF 4th,Fonarow GC,Emerman CL,et al.Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE[J].Cardiology,2007,107(1):44-51.
[73]Moazami N,Damiano RJ,Bailey MS,et al.Nesiritide (BNP)in the management of postoperative cardiac patients[J].Ann Thorac Surg,2003,75(6):1974-1976.
[74]Takaoka H,Takeuchi M,Hata K,et al.Beneficial effects of a Ca~(2+)sensitizer,MCI-154,on the myocardial oxygen consumption cardiac output relation in patients with left ventricular dysfunction after myocardial infarctionxomparison with dobutamine and phosphodiesterase inhibitor[J].Am Heart J,1997,133(3):283-289.
[75]Mori M,Takeuchi M,Takaoka H,et al.Lusitropic effects of a Ca~(2+)sensitization with a new cardiotonic agent,MCI-154,on diseased human hearts[J].Cardiovasc Res,1995,30(6):915-922.
[76]Follath F,Cleland JG,Just H,et al.Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study):a randomised double-blind trial[J].Lancet,2002,360(9328):196-202.
[77]Moiseyev VS,Poder P,Andrejevs N,et al.Safety and efficacy of a novel calcium sensitizer,levosimendan,in patients with left ventricular failure due to an acute myocardial infarction.A randomized,placebo-controlled,double-blind study (RUSSLAN)[J].Eur Heart J,2002,23(18):1422-1432.
[78]Fazio S,Sabatini D,Capaldo B,et al.A preliminary study of growth hormone in the treatment of dilated cardiomyopathy[J].N Engl J Med,1996,334(13):809-814.
[79]Osterziel KJ,Strohm O,Schuler J,et al.Randomised,double-blind,placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy[J].Lancet,1998,351(9111):1233-1237.
[80]Isgaard J,Bergh CH,Caidahl K,et al.A placebo-controlled study of growth hormone in patients with congestive heart failure[J].Eur Heart J,1998,19(11):1704-1711.
[81]谭真,刘兴斌.心脏再同步治疗研究现状[J].心血管病学进展,2008,29(2):228-231.
[82]Cazeau S,Ritter P,Bakdach S,et al.Four chamber pacing in dilated cardiomyopathy[J].Pacing Clin Electrophysiol,1994,17(11 Pt 2):1974-1979.
[83]Anand IS,(2arson P,Galle E,et al.Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure:results from the Comparison of Medical Therapy,Pacing and Defibrillation in Heart Failure(COMPANION) trial[J].Circulation.2009,119(7):969-977.
[84]Cleland JG,Daubert JC,Erdmann E,et al.The effect of cardiac resynchronization on morbidity and mortality in heart failure[J].N Engl J Med,2005,352(15):1539-1549.
[85]Rossi A,Rossi G,Piacenti M,et al.The current role of cardiac resynchronization therapy in reducing mortality and hospitalization in heart failure patients:a meta-analysis from clinical trials[J].Heart Vessels,2008,23(4):217-23.
[86]Vardas PE,Auricchio A,Blanc JJ,et al.Guidelines for cardiac pacing and cardiac resynchronization therapy:The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology.Developed in collaboration with the European Heart Rhythm Association.[J].Eur Heart J,2007,28(18):2256-2295.
[87]Gasparini M,Auricchio A,Regoli F,et al.Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression:the importance of performing atrioventricular junction ablation in patients with atrial fibrillation[J].J Am Coll Cardiol,2006,48(4):734-743.
[88]Greenberg H,Case RB,Moss AJ,et al.Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial(MADIT-Ⅱ)[J].J Am Coll Cardiol,2004,43(8):1459-1465.
[89]Bardy GH,Lee KL,Mark DB,et al.Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure[J].N Engl J Med,2005,352(3):225-237.
[90]Wilkoff BL,Cook JR,Epstein AE,et al.Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator:the Dual Chamber and VVI Implantable Defibrillator(DAVID) Trial[J].JAMA,2002,288(24):3115-23.
[91]Dec GW.Management of heart failure:crossing boundary over to the surgical country[J].Surg Clin North Am,2004,84(1):1-25.
[92]胡盛寿,郑哲.心力衰竭的进展(9)终末期心力衰竭的外科治疗[J].中国循环杂志,2006,21(4):243-245.
[93]Dec GW.Management of heart failure;crossing boundary over to the country[J].Surg Clin N Am,2004,84(1):1-25.
[94]Rose EA,Gelijns AC,Moskowitz AJ,et al.Long-term mechanical left ventricular assistance for end-stage heart failure[J].N Engl J Med,2001,345(20):1435-1443.
[95]Curtis JP,Sokol SI,Wang Y,et al.The association of left ventricular ejection fraction,mortality,and cause of death in stable outpatients with heart failure[J].J Am Coll Cardiol,2003,42(4):736-742.
[96]de Bold AJ,Bruneau BG,Kuroski de Bold ML.Mechanical and neuroendocrine regulation of the endocrine heart[J].Cardiovasc Res,1996,31(1):7-18.
[97]Clerico A,Iervasi G,Del Chicca MG,et al.Circulating levels of cardiac natriuretic peptides (ANP and BNP)measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure[J].J Endocrinol Invest.1998,21(3):170-179.
[98]Wallen T,Landahl S,Hedner T,et al.Brain natriuretic peptide predicts mortality in the elderly[J].Heart 1997,77(3):264-267.
[99]Cheng V,Kazanagra R,Garcia A,et al.A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure:a pilot study[J].J Am Coll Cardiol,2001,37(2):386-391.
[100]Doust JA,Pietrzak E,Dobson A,et al.How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure:systematic review[J].BMJ,2005,330(7492):625.
[101]Murdoch DR,McDonagh TA,Byrne J,et al.Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration:randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy [J].Am Heart J,1999,138(6 Pt 1):1126-1132.
[102]Beck-da-Silva L,de Bold A,Fraser M,et al.BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure[J].Congest Heart Fail,2005,11(5):248-53;quiz 254-255.
[103]Guyatt GH.Measurement of health-related quality of life in heart failure[J].J Am Coll Cardiol,1993,22(4 SupplA):185A-191A.
[104]Morgan K,McGee H,Shelley E.Quality of life assessment in heart failure interventions:a 10-year (1996-2005)review[J].Eur J Cardiovasc Prev Rehabil,2007,14(5):589-607.
[105]Garin O,Ferrer M,Pont A,et al.Disease-specific health-related quality of life questionnaires for heart failure:a systematic review with meta-analyses [J].Qual Life Res,2009,18(1):71-85.
[106]Heo S,Moser DK,Riegel B,et al.Testing the psychometric properties of the Minnesota Living with Heart Failure questionnaire [J].Nurs Res,2005,54(4):265-272.
[107]O'Keeffe ST,Lye M,Donnellan C,et al.Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients[J].Heart,1998,80(4):377-382.
[108]Cahalin L,Mathier M,Semigran M,et al.The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure[J].Chest,1996,110(2):325-332.
[109]Solway S,Brooks D,Lacasse Y,et al.A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain[J].Chest,2001,119(1):256-270.
[110]Opasich C,Pinna GD,Mazza A,et al.Six-minute walking performance in patients with moderate-to-severe heart failure:Is it a useful indicator in clinical practice?[J].Eur Heart J 2001,22(6):488-496.
[111]Olsson LG,Swedberg K,Clark AL,et al.Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized,blinded intervention trials of chronic heart failure:a systematic review[J].Eur Heart J.2005,26(8):778-793.
[112]ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.ATS Statement:Guidelines for the Six-Minute Walk Test[J].Am J Respir Crit Care Med.2002,166(1):111-117.
[113]Ishino M,Takeishi Y,Niizeki T,et al.Risk stratification of chronic heart failure patients by multiple biomarkers:implications of BNP,H-FABP,and PTX3[J].Circ J,2008,72(11):1800-1805.
[114]Dokainish H.Combining tissue Doppler echocardiography and B-type natriuretic peptide in the evaluation of left ventricular filling pressures:review of the literature and clinical recommendations[J].Can J Cardiol,2007,23(12):983-989.
[115]Castellanos LR,Bhalla V,Isakson S,et al.B-type natriuretic peptide and impedance cardiography at the time of routine echocardiography predict subsequent heart failure events[J].J Card Fail,2009,15(1):41-47.
[107]顾东风,黄广勇,何江,等.中国心力衰竭流行病学调查及其患病率[J].中华心血管病杂志,2003,31(10):3-6.
[1]国家药典委员会.中华人民共和国药典[M].北京:化学工业出版社,2005:232-233.
[2]张慧.黄芪注射液治疗小儿病毒性心肌炎107例疗效分析[J].中国保健医学研究版,2008,16(14):687-688.
[3]于凤秀.黄芪注射液治疗急性病毒性心肌炎的临床观察[J].中西医结合心脑血管病杂志,2008,6(9):1100-1101.
[4]刘慧玲,赵卫国.黄芪注射液治疗病毒性心肌炎疗效观察[J].2008,17(3):329-332
[5]杨顺昱.黄芪注射液合用环磷腺苷葡胺治疗急性病毒性心肌炎的疗效观察[J].广西医学,2008,30(5):649-650.
[6]陈晓培,张耕.黄芪注射液治疗小儿病毒性心肌炎疗效观察[J].中国医院药学杂志,2007,27(9):1270-1271.
[7]刘冰,张辉.黄芪注射液佐治病毒性心肌炎疗效观察[J].中国妇幼保健,2005,20(20):2697-2698.
[8]宁亚兰,郭霞.黄芪注射液治疗急性病毒性心肌炎51例[J].陕西医学杂志,2005,34(6):729-730.
[9]苏群,方强.黄芪注射液联用西药治疗急性病毒性心肌炎对血自然杀伤细胞活性及可溶性白介素-2受体水平的影响[J].中国中西医结合急救杂志,2000,7(2):75.
[10]沈菊英,龚祖埙,杨英珍,等.黄芪对培养的大鼠搏动心肌细胞感染柯萨奇B_2病毒后保护作用的超微观察[J].细胞生物学杂志,1986,(2):87-89.
[11]郭棋,彭天庆,杨英珍,等.黄芪对柯萨奇B3病毒感染培养大鼠心肌细胞Ca2+内流及该病毒RNA复制的影响[J].中国中西医结合杂志,1995,15(8):483.
[12]蒋丽敏,魏克伦,李微,等.黄芪注射液对柯萨奇B3心肌炎小鼠心肌穿孔素表达[J].中成药,2002,24(11):857-859.
[13]曹洪欣,刘寨华,张华敏.基于聚类分析的病毒性心肌炎证候分类及证候特征研究[J].2007,48(7):629-632.
[14]林谦,王硕仁,吕唏莹,等.党参黄芪治疗心气虚型冠心病的初步观察[J].北京中医,1990,12(1):33.
[15]姚萍,雷艳蓉,唐恩东.黄芪注射液治疗冠心病心绞痛的临床观察[J].四川中医,2004,22(7):52-53.
[16]王翠兰,胡英华,张蕾,等.黄芪注射液对冠心病患者血液流变性的影响[J].微循环学杂志,2000,10(1):50.
[17]张彦梅.黄芪注射液对冠心病左心室收缩功能的影响山西医学杂志[J].1997,26(5):424-425.
[18]曹志军,杨汉光.大剂量黄芪注射液治疗冠心病心纹痛68例临床观察[J].北京中医,1997,16(3):27-29.
[19]韩光辉.大剂量黄芪注射液治疗冠心病88例[J].河南医科大学学报,1999,34(4):85.
[20]刘建勤.黄芪注射液治疗冠心病心绞痛的临床研究[J].时珍国医国药,2007, 18(9):2259-2260.
[21]李乙根.黄芪注射液联合川芎嗪注射液治疗冠心病不稳定型心绞痛46例临床观察[J].2008,40(6):35-36.
[22]单乃静.普泽川芎嗪合黄芪注射液治疗冠心病心绞痛60例疗效观察[J].时珍国医国药,2004,15(8):506-507.
[23]王兴,陈蓉,刘宝红.黄芪注射液治疗冠心病心绞痛及其对血浆vWF、CEC的影响[J].上海中医药杂志,2005,39(7):12-13.
[24]徐军,黄象娟,齐法莲,等.络泰和黄芪注射液对冠心病患者血浆中ET-1和vWF的影响[J].中国免疫学杂志,2003,19(2):128.
[25]陈志群,郭梅煌,马建芳,等.黄芪注射液对冠心病患者C反应蛋白和体液免疫的影响[J].使用中西医结合临床,2001,1(1):3-4.
[26]易思,劳卫国,李燕.黄芪注射液合复方丹参注射液为主治疗肺心病45例疗效观察[J].新中医,2002,34(7):30-31.
[27]杨芝芸.黄芪注射液治疗高原肺心病心衰65例[J].辽宁中医杂志,1997,24(6):261.
[28]韩舒秀,郑晓兰.老年慢性肺心病患者脂质过氧化损伤与病情演变的关系[J].中国医学研究与临床.2004,2(2):64-65.
[29]赵淑杰.硝酸甘油联合黄芪注射液治疗肺心病心功能不全的临床观察[J].吉林医学,2007,28(10):1224.
[30]刘浩,陈爱萍.黄芪注射液对慢性肺心病患者血中脂质过氧化物及抗氧化酶活性的影响[J].中国医院药学杂志,2006,26(11):1340-1342.
[31]高殿富.黄芪注射液对肺心病病人超氧化物歧化酶水平的影响[J].中国新药与临床杂志,1999,18(6):376-377.
[32]余静,郭雪娅,赵锋,等.黄芪注射液对高血压病患者血浆P选择素、血栓素B2及6-酮前列环素F1α的影响[J].临床荟萃,2005,20(13):721-722.
[33]郭惠莲.复方丹参和黄芪注射液辅助治疗肺心病的疗效[J].第四军医大学学报,2003,24(14):封3.
[34]李洪涛.低分子量肝素联合地奥黄芪注射液治疗肺心病30例临床观察[J].中原医刊,2005,32(8):39-40.
[35]郭健,施慧娟.丹参黄芪注射液配合西药治疗肺心病的急性发作期42例[J].陕西中医,2002,23(10):879-880.
[36]朱子阳.黄芪注射液辅助治疗肺心病急性加重期的临床观察[J].中国中西医结合杂志,2001,21(4):268.
[37]梁晶,熊岳玲.黄芪注射液治疗肺心病疗效观察[J].中药药理与临床,1999,15(6):43-44.
[38]周波,张小燕,常中凡,等.黄芪注射液辅助治疗肺心病心力衰竭64例[J].1999,18(6):374-375.
[39]张忠德,黄东晖,毛炜,等.黄芪注射液对肺心病患者血清地高辛浓度的影响[J].新中医,1999,31(4):35-36.
[40]张莹,梁晋普,指导:郭维琴.郭维琴教授治疗病态窦房结综合征经验拾萃[J].实用中医内科杂志,2005,19(3):210.
[41]马玲.参附黄芪注射液治疗病态窦房结综合征23例[J].医药论坛杂志.2005,26(22):43.
[42]邱勇.温阳活血饮配合黄芪注射液治疗病态窦房结综合征31例[J].福建中医药,2003,34(1):29.
[43]郑新玲.黄芪注射液治疗病态窦房结综合征疗效观察[J].中西医结合实用临床急救,1999,6(3):133-134.
[44]王宏伟,郭芳,谢岩屏.黄芪注射液治疗冠心病所致病窦综合征40例[J].中国中医药信息杂志,1999,6(12):56.
[45]黄平东.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4):592-593.
[46]李南夷,邓铁涛,文旺秀.心衰证治研究概述[J].中医药信息,1995,(5):6-10.
[47]黄平东,罗懿明,黄衍寿,等.充血性心力衰竭中医证型特征及其演变规律的临床观察[J].中西医结合心脑血管病杂志,2000,1(12):685-686.
[48]任澎,程祖亨,马依彤.黄芪注射液对充血性心力衰竭患者的急性血液动力学效应[J].中国中西医结合杂志,1998,18(8):460.
[49]张金国,高东升,谭洪勇,等.黄芪注射液对老年充血性心力衰竭患者血浆促炎性细胞因子的影响[J].济宁医学院学报,2006,29(2):13-15.
[50]焦雄文,段颖.黄芪注射液对充血性心力衰竭左心室重构影响的临床研究.陕西中医学院学报[J].2006,29(3):19-20.
[5l]周智林,俞娉,林玎.黄芪注射液治疗充血性心力衰竭的疗效研究[J].中国中西药结合杂志,2001,21(10):747-749.
[52]严萍萍,张文芳,李勇,等.黄芪注射液对心力衰竭患者神经内分泌系统的影响.中华使用中西医杂志[J].2004,4(17):3188-3189.
[53]刘志高,熊正明,余细勇.黄芪注射液对充血性心力衰竭患者免疫功能的影响[J].中国中西医结合杂志[J].2003,23(5):351-353.
[54]柯晓,周宗梅,文明.黄芪注射液辅助治疗充血性心力衰竭的疗效及对免疫调节影响的观察[J].药学实践杂志,2004,22(5):268-269.
[55]卢威志,李玉光.黄燕注射液对心肌细胞缺氧献糖/复氧复糖损伤保护作用的实验研究[J].实用中西医结合杂志,1998.11(1):10-11.
[56]顾娟红,沈惟堂,李自普,等.黄芪对缺血大鼠心肌钙厦脂质过氧化物的影响[J].上海医科大学学报,1997,24(4):270-271.
[57]冯国清,秦晓晨,刘洁,等.黄芪对太鼠心肌罐血再灌注损伤的防护作用[J].中药药理与临床,1997,13(3):27-28.
[1]张子彬,Tsung O.Cheng,张玉传.充血性心力衰竭学[M].第1版.北京:科学技术文献出版社,2002:3-24,156-172,551-570.
[2]Ren(?)e Ventura-Clapier,Anne Garnier,Vladimir Veksler.Energy metabolism in heart failure[J].J Physiol,2004,555(Pt 1):1-13.
[3]Taegtmeyer H,Hems R,Krebs HA.Utilization of energy providing substrates in the isolated working rat heart[J].Biochem J,1980,186(3):701-711.
[4]Fujii N,Nozawa T,Igawa A,et al.Saturated glucose uptake capacity and impaired fatty acid oxidation in hypertensive hearts before development of heart failure[J].Am J Physiol Heart Circ Physiol,2004,287(2):H760-H766.
[5]de las Fuentes L,Herrero P,Peterson LR,et al.Myocardial Fatty Acid Metabolism:Independent Predictor of Left Ventricular Mass in Hypertensive Heart Disease[J].Hypertension,2003,41(1):83-87.
[6]Lopaschuk GD.Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure[J].Semin Cardiothorac Vasc Anesth,2006,10(3):228-230.
[7]Sack MN,Rader TA,Park,et al.Fatty acid oxidation enzyme gene expression is downregulated in the failing heart[J].Circulation,1996,94(11):2837-2842.
[8]Razeghi,P,Young,ME,Alcorn JL,et al.Metabolic gene expression in fetal and failing human heart[J].Circulation,2001,104(24):2923-2931.
[9]Pellieux C,Aasum E,Larsen TS,et al.Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway[J].J Mol Cell Cardiol,2006,41(3):459-466.
[10]殷仁富,陈金明.心脏能量学-代谢与治疗[M].第1版.上海:第二军医大学出版社,2002:151-181.
[11]Lionetti V,Linke A,Chandler MP,et al.Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure[J].Cardiovasc Res,2005,66(3):454-461.
[12]Rupp H,Rupp TP,Maisch B.Metabolism and the hypertrophied heart of the elderly[J].Dtsch Med Wochenschr,2005,130(12):726-730.
[13]Chen R,Liang F,Moriya J,et al.Peroxisome proliferator-activated receptors(PPARs) and their agonists for hypertension and heart failure:are the reagents beneficial or harmful?[J].Int J Cardiol,2008,130(2):131-139..
[14]Young ME,Laws FA,Goodwin OW,et al.Reactivation of peroxisome proliferator-activated receptor is associated with contratile with dysfunction in hypertrophied rat heart[J].J Biol ChEM,2001,276(48):44390-44395.
[15]Schupp M,Kintscher U,Fielitz J,et al.Cardiac PPARalpha expression in patients with dilated cardiomyopathy[J].Eur J Heart Fail,2006,8(3):290-294.
[16]Chen R,Liang F,Moriya J,et al.Peroxisome proliferator-activated receptors(PPARs) and their agonists for hypertension and heart failure:are the reagents beneficial or harmful?[J].Int J Cardiol,2008,130(2):131-139.
[17]Alibin CP,Kopilas MA,Anderson HD.Suppression of cardiac myocyte hypertrophy by conjugated linoleic acid:role of peroxisome proliferator-activated receptors alpha and gamma[J].J Biol Chem,2008,283(16):10707-10715.
[18]Faquan FQ,Wang F,Zhang SM,et al.Peroxisome proliferator activated receptor(PPAR)agonists inhibit hypertrophy of neonatal rat cardiac myocytes[J].Endocrinology,2003,144(9):4187-4194.
[19]胡琴,李隆贵,耿昭华.压力负荷性大鼠肥厚心肌过氧化物酶体增殖剂活化受体(PPARα)和卡尼汀棕榈酰转移酶(M-CPT-I)mRNA的表达变化[J].高血压杂志,2003,11(1):65-68.
[20]Orchard C,Kentish J.Effects of changes of pH on the contractile function of cardiac muscle[J].Am J Physiol,1990,258(6 Pt 1):C967-C981.
[21]Friehs I,Moran AM,Stamm C,et al.Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure[J].Circulation,1999,100(19 Suppl):Ⅱ187-Ⅱ193.
[22]Joost HG,Thorens B.The extended GLUT-family of sugar/polyol transport facilitators:nomenclature,sequence characteristics,and potential function of its novelmembers[J].MolMembrBiol,2001,18(4):247-256.
[23]Tian R,Musi N,Agostino J,et al.Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy[J].Circulation,2001,104(14):1664-1649.
[24]Abel ED,Kaulbach HC,Tian R,et al.Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart[J].J Clin Invest,1999,104(12):1703-1714.
[25]Liao R;Jain M;Cui L,et al.Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice[J].CirCulation.2002,106(16):2125-2131.
[26]McFalls EO,Murad B,Liow JS,et al.Glucose uptake and glycogen levels are increased in pig heart after repetitive ischemia[J].Am J Physiol Heart Circ Physiol,2002,282(1):205-211.
[27]杭 涛综述,江时森审校.葡萄糖转运子的表达和功能与心力衰竭的关系[J].医学研究生学报,2008,21(3):302-305.
[28]Ramasamy R,Hwang YC,Whang J,et al.Protection of ischemic heartsby high glucose ismediated,in part,by GLUT-4[J].Am J Physiol Heart Circ Physiol,2001,281(1):290-297.
[29]Tian R,Abel ED.Response of GLUT4-deficient hearts to ischemia under score the importance of glycolysis[J].Circulation,2001,103(24):2961-2966.
[30]Taegtmeyer H.Switching metabolic genes to build a better heart[J].Circulation,2002,106(16):2043-2045.
[31]苏静泽.黄芪组分对肥厚心肌能量代谢的干预作用及机制探讨[D].2008:10.
[32]Kakinuma Y,Miyauchi T,Yuki K,et al.Novel molecular mechanism of increased myocardial endothelin-1 expression in the failing heart involving the transcriptional factor hypoxia-inducible factor-lalpha induced for impaired myocardial energy metabolism[J].Circulation,2001,103(19):2387-2394.
[33]Zolk O,Solbach TF,Eschenhagen T,et al.Activation of negative regulators of the hypoxia-inducible factor(HIF) pathway in human end-stage heart failure[J].Biochem Biophys Res Commun,2008,376(2):315-320.
[34]Weidemann A,Klanke B,Wagner M,et al.Hypoxia,via stabilization of the hypoxia-inducible factor HIF-lalpha,is a direct and sufficient Stimulus for brain-type natriuretic peptide induction[J].Biochem J,2008,409(1):233-242.
[35]Huss JM,Kelly DP.Mitochondrial energy metabolism in heart failure:a question of balance[J].J Clin Invest,2005,115(3):547-555.
[36]Michell P.Keilin's respiratory chain concept and its chemiosmotic consequences[J].Science,1979,206(4423):1148-1159.
[37]Pallock M,Phaneuf S,Dirks A,et al.The role of apoptosis in the normal aging brain,skeletal muscle,and heart[J].Ann NY Acad Sci,2002,959:93-107.
[38]Moon CH,Jung YS,Kim MH,et al.Protein kinase C inhibitors attenuate protective effect of high glucose against hypoxic injury in H9c2 cardiac cells[J].Jpn J Physiol,2000,50(6):645-649.
[39]Kim MH,Jung YS,Moon CH,et al.High-glucose induced protective effect against hypoxic injury is associated with maintenance of mitochondrial membrane potential[J].Jpn J Physiol.2003,53(6):451-459.
[40]Sharma AK,Dhingra S,Khaper N,et al.Activation of apoptotic processes during transition from hypertrophy to heart failure in guinea pigs[J].Am J Physiol Heart Circ Physiol,2007,293(3):H1384-H1390.
[41]Lin L,Sharma VK,Sheu SS.Mechanisms of reduced mitochondrial Ca2+ accumulation in failing hamster heart[J].Pflugers Arch,2007,454(3):395-402.
[42]Hansson A,Hance N,Dufour E,et al.A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts[J].Proc Natl Acad Sci USA,2004,101(9):3136-3141.
[43]Quigley AF,Kapsa RM,Esmore D,et al.Mitochondrial respiratory chain activity in idiopathic dilated cardiomyopathy[J].J Card Fail.2000,6(1):47-55.
[44]陈丽芬.缺氧对大鼠脑线粒体氧化呼吸功能和ANT活性及异构体表达的影响[D].2004:44.
[45]Portman MA.The adenine nucleotide translocator:regulation and function during myocardial development and hypertrophy[J].Clin Exp Pharmacol Physiol,2002,29(4):334-338.
[46]Yamazaki N,Shinohara Y,Tanida K,et al.Structural properties of mammalian mitochondrial ADP/ATP carriers:identification of possible amino acids that determine functional differences in its isoforms[J].Mitochondrion,2002,1(4):371-379.
[47]Doerner A,Pauschinger M,Badoeff A,et al.Tissue-specific transcription pattern of the adenine nucleotide translocase isoforms in humans[J].FEBS Lett,1997,414(2):258-262.
[48]D(o|¨)rner A,Olesch M,Giessen S,et al.Transcription of the adenine nucleotide translocase isoforms in various types of tissues in the rat[J].Biochimicaet Biophysica Acta,1999,1417(1):16-24.
[48]李兵,柳君泽,陈丽芬.缺氧对大鼠心肌线粒体能量代谢和腺苷酸转位酶活性的影响[J].中国病理生理杂志,2006,22(3):460-463.
[50]李兵.缺氧过程中大鼠心肌线粒体能量代谢和腺苷酸转位酶活性及表达的研究[D].2004:30.
[51]伊木清,杨志勇,许葆华,等.游泳训练和硒缺乏对大鼠血清睾酮及心肌线粒体钙流入的影响[J].中国运动医学杂志,2000,19(4):353-355.
[52]Gunter TE,Buntinas L,Sparagna G,et al.Mitochondrial calcium transport:mechanisms and functions[J].Cell Calcium,2000,28(5-6):285-296.
[53]徐美英,马宇,王学敏,等.缺血再灌注损伤对兔心肌线粒体钙稳态的影响[J].2002,23(2):186-188.
[54]沈同,王镜岩.生物化学[M].第1版,北京:高等教育出版社,1991:17-18.
[55]Neubauer S,Horn M,Cramer M,et al.Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy[J].Circulation,1997,96(7):2190-2196.
[56]Beer M,Seyfarth T,Sandstede J,et al.Absolute concentrations of high-energy phosphate metabolites in normal,hypertrophied,and failing human myocardium measured noninvasively with(31)P-SLOOP magnetic resonance spectroscopy[J].J Am Coll Cardiol,2002,40(7):1267-1274.
[57]DU XH,Liang FY,Zhao XW.Effects of phosphocreatine on plasma brain natriuretic peptide level in elderly patients with chronic congestive heart failure[J].Nan Fang Yi Ke Da Xue Xue Bao,2009,29(1):154-155.
[58]沈炳权,陈明,朱霞,等.磷酸肌酸钠对慢性心衰患者心功能的影响[J].浙江中西医结合杂志,2008,18(1):15-16.
[59]Bessman SP,Geiger PJ.Transport of energy in muscle:the phosphorylcreatine shuttle[J],Science,1981,211(4481):448-452.
[60]Neubauer S,Frank M,Hu K,et al.Changes of creatine kinase gene expression in rat heart post-myocardial infarction[J].J Mol Cell Cardiol,1998,30(4):803-810.
[61]Ye Y,Wang C,Zhang J,et al.Myocardial creatine kinase kinetics and isoform expression in hearts with severe LV hypertrophy[J].Am J Physiol Heart Circ Physiol,2001, 281(1):H376-H386.
[62]Nascimben L,Ingwall JS,Pauletto P,et al.Creatine kinase system in failing and nonfailing human myocardium[J].Circulation,1996,94(8):1894-1901.
[63]Spindler M,Engelhardt S,Niebler R,et al.Alterations in the myocardial,creatine kinase system precede the development of contractile dysfunction in beta(1)-adrenergic receptor transgenic mice[J].J Mol Cell Cardiol,2003,35(4):389-397.
[64]Lygate CA,Fischer A,Sebag-Montefiore L,et al.The creatine kinase energy transport system in the failing mouse heart[J].J Mol Cell Cardiol,2007,42(6):1129-1136.
[65]Ye Y,Gong G,Ochiai K,et al.High-energy phosphate metabolism and creatine kinase in failing hearts:a new porcine model[J].Circulation,2001,103(11):1570-1576.
[66]Ventura-Clapier R,Kuznetsov AV,d'Albis A,et al.Muscle creatine kinase-deficient mice:alterations in myofibrillar function[J].J Biol Chem,1995,270(34):19914-19920.
[67]Dzeja PP,Vitkevicius KT,Redfield MM,et al.Adenylate kinase-catalyzed phosphotransfer in the myocardium:increased contribution in heart failure[J].Circulation Research,1999,84(10):1137-1143.
[68]农一兵,苏敬泽,温志浩,等.从补益心气与改善心肌能量代谢的关系探讨慢性心力衰竭中西医结合研究的思路[J].中医杂志,2007,48(11):1035-1036.
[69]廖家桢,林谦,于友华.心气虚证的中西医结合研究中药药理与临床研究进展(第四册,周金黄,王建华主编)[M].第1版.北京:军事医学科学出版社,1996:111-124.
[70]洪缨,许少珍,曾德源,等.黄芪注射液对慢性心衰大鼠心肌肥厚的逆转作用[J].中成药,2002,24(7):525-529.
[71]于忠学,关丽梅,王炎焱,等.复方黄芪无糖颗粒对心肌缺血能量代谢的影响[J].中医药信息,2003,20(1):55.
[1]薛振怀,黄伯梯,代早荣.黄芪注射液治疗充血性心力衰竭的临床观察[J].内蒙古中医药,2007,26(5):10-11
[2]李建辉,徐波,薛冀苏,等.硝普钠联合黄芪注射液治疗充血性心力衰竭的疗效观察[J].中国热带医学,2007,7(8):1343-1344
[3]王丽.黄芪注射液对肺心病心衰血清酶影响及疗效观察[J].实用中医内科杂志,2007,21(4):79-80
[4]吕培轩,郭清军.黄芪注射液治疗难治性心力衰竭30例疗效观察[J].哈尔滨医药,2007,27(4):21-22
[5]尚伟民,马敏芳.黄芪注射液治疗扩张型心肌病心力衰竭36例[J].中原医刊,2007,34(23):80
[6]杨勇娟.黄芪注射液结合西药治疗充血性心力衰竭的疗效观察[J].中外健康文摘·医药月刊,2007,4(11):31-32
[7]韦育林,李楚强,陈锡龙,等.黄芪注射液对充血性心力衰竭患者细胞因子和血管紧张素Ⅱ的影响[J].中国临床康复,2006,10(3):54-56
[8]张金国,高东升,谭洪勇,等.黄芪注射液对老年充血性心力衰竭患者血浆促炎性细胞因子的影响[J].济宁医学院学报,2006,29(2):13-15
[9]刘珠章.黄芪注射液治疗慢性心力衰竭对心输出量的影响[J].中华现代内科学杂志,2006,3(5):553-554
[10]黄建平.黄芪注射液治疗肺心病心衰40例临床观察[J].中国现代医药杂志,2006,8(9):25
[11]常健梅,王霞.卡维地洛配伍黄芪注射液治疗慢性心力衰竭25例疗效观察[J].陕西医学杂志,2006,35(5):601-602,609
[12]焦雄文,段颖.黄芪注射液对充血性心力衰竭左心室重构影响的临床研究[J].陕西中医学院学报2006,29(3):19-20
[13]李玉侠.黄芪注射液治疗老年慢性心力衰竭疗效观察[J].基层医学论坛(B版),2006,10(5):419-420
[14]杨水娥,彭爱英,李红燕.黄芪注射液治疗慢性心力衰竭疗效的研究[J].中华实用中西医杂志,2006,19(10):1111,1113
[15]郭辉,陈红伟.黄芪注射液治疗慢性充血性心力衰竭42例[J].中原医刊,2006,33(2):85-86
[16]陆振涛,赵大国,刘勇.黄芪注射液治疗冠心病心力衰竭的临床观察[J].基层医学论坛(B版),2006,10(1):1-2
[17]王恒和.黄芪注射液辅助治疗难治性心力衰竭临床研究[J].中国中医急症,2005,14(11):1070-1071
[18]曾健球,郭秀春,汪锦丹,等.黄芪注射液治疗充血性心力衰竭36例[J].河南中医,2005,25(11):71
[19]高建辉.黄芪注射液治疗充血性心力衰竭临床观察[J].广东药学院学报,2005,21(5):610-611
[20]马玲,余俊丽,韩月锋.黄芪注射液治疗肺原性心脏病顽固性心力衰竭临床观察[J].河南中医,2005,25(10):78-79
[21]席周让,金晓琴.黄芪注射液治疗充血性心力衰竭的疗效观察[J].现代医药卫生,2005,21(17):2337-2338
[22]胡小松,王晓娟.黄芪注射液治疗充血性心力衰竭临床观察[J].现代医药卫生,2005,21(17):2333-2334
[23]过海东,刘龙华,元文峰,等.黄芪注射液治疗慢性肺心病合并心衰的疗效观察[J].实用中西医结合临床,2005,5(4):22
[24]郭宝云.黄芪注射液治疗充血性心力衰竭65例疗效观察[J].新疆医科大学学报,2005,28(7):662-663
[25]罗康华,陈实亭.黄芪注射液对慢性充血性心力衰竭左心功能的影响[J].中原医刊,2005,32(10):52
[26]张金国,杨娜,何华,等.黄芪注射液对慢性心力衰竭患者血浆凋亡相关因子的影响[J].中国中西医结合杂志,2005,25(5):400-403
[27]刘有才.黄芪注射液治疗老年心力衰竭疗效观察[J].新乡医学院学报,2005,22(3):244-245
[28]刘英芹,李芸.黄芪注射液治疗充血性心力衰竭临床研究[J].实用中医药杂志,2005,21(4):198-199
[29]吴新华,陈康文.黄芪注射液治疗扩张型心肌病心力衰竭26例疗效观察[J].云南中医中药杂志,2005,26(1):13
[30]董青,吴先旺,张敬芳.黄芪注射液治疗充血性心力衰竭61例疗效观察[J].现代医药卫生,2005,8(3):285-286
[31]刘爱好.黄芪注射液治疗慢性充血性心力衰竭临床观察[J].浙江中西医结合杂志,2005,15(1):32-33
[32]李敏慧,彭景拾.黄芪注射液治疗慢性肺心病心力衰竭疗效观察[J].医药论坛杂志,2004,25(24):57
[33]张晋生.黄芪注射液治疗充血性心力衰竭疗效观察[J].实用医技杂志,2004,11(12A):2617
[34]李靖.黄芪注射液治疗充血性心力衰竭的疗效观察[J].华北煤炭医学院学报,2004,6(6):746
[35]柯晓,周宗梅,文明,等.黄芪注射液辅助治疗充血性心力衰竭的疗效及对免疫调节影响的观察[J].药学实践杂志,2004,22(5):268-270
[36]刘彩红,李英华.黄芪注射液治疗充血性心力衰竭临床观察[J].辽宁中医学院学报,2004,6(5):390
[37]严萍萍,张文芳,李勇,等.黄芪注射液对心力衰竭患者神经内分泌系统的影响[J].中华实用中西医杂志,2004,17(21):3188-3190
[38]吴莉雯.黄芪注射液治疗慢性肺心病心力衰竭的疗效观察[J].新疆医学,2004,34(4):107-108
[39]张少峰,王廷会,黄芪注射液治疗慢性充血性心力衰竭49例[J].临床心血管病杂志,2004,20(8):496
[40]侯桂萍.黄芪注射液联合硝酸甘油治疗充血性心力衰竭[J].中华中西医临床杂志,2004,4(7):879
[41]程杭,贾连旺.黄芪注射液治疗老年退行性心脏瓣膜病心功能不全[J].浙江中西医结合杂志,2004,14(6):347-348
[42]罗庆东,王艳霞,胡敏.黄芪注射液配合常规疗法治疗老年慢性充血性心力衰竭46例疗效观察[J].黑龙江中医药,2004,(3):8-9
[43]祝星,叶红华,王胜煌,等.黄芪注射液治疗难治性心力衰竭疗效观察[J].浙江中西医结合杂志,2004,14(5):268-270
[44]张玉伟.黄芪注射液治疗重症充血性心力衰竭的疗效观察[J].中华现代中西医杂志,2004,2(4):311-312
[45]谭敏豪,范金让.地奥黄芪注射液治疗心力衰竭疗效观察[J].中华临床医学研究杂志,2004,10(89):1092-1093
[46]尹乐安.黄芪注射液对肺心病心力衰竭心功能的影响:附102例报告[J].中国医师杂志,2004,6(3):427
[47]原广平.黄芪注射液治疗慢性心力衰竭的临床疗效评价[J].中国临床药靼学与治疗学,2003,8(6):710-711
[48]李书瑞,郝建峰,武付忠,等.不同剂量黄芪注射液治疗充血性心力衰竭临床疗效观察[J].中华实用中西医杂志,2003,16(12):1665-1667
[49]顾旭,尚树忠,郭锐.黄芪注射液辅助治疗充血性心力衰竭68例[J].医药导报,2003,22(8):556-557
[50]房泽岱,秦元玲.黄芪注射液治疗充血性心力衰竭的临床观察[J].中原医刊,2003,30(14):6-7
[51]蔡静,李雪萍,陈鹏.黄芪注射液治疗肺心病并心衰56例疗效观察[J].中华医学写作杂志,2003,10(12):1097-1098
[52]刘芬,付兰慧.黄芪注射液治疗充血性心力衰竭[J].临床荟萃,2003,18(11):639
[53]王希宁.美托洛尔联用黄芪注射液治疗缺血性心脏病心力衰竭35例临床碑察[J].湖南中医药导报,2003,9(5):15-17
[54]孙晓鸣.黄芪注射液治疗肺原性心脏病心力衰竭40例疗效观察[J].齐齐哈尔医学院学报,2003,24(5):520
[55]刘志高,熊正明,余细勇.黄芪注射液对充血性心力衰竭患者免疫功能的影响[J].中国中西医结合杂志,2003,23(5):351-353
[56]曾和松,吴正贤,刘正湘,等.黄芪注射液治疗心功能不全并心律失常的临床观察[J].实用心脑肺血管病杂志,2003,11(2):70-72
[57]智宏民,史晓婧.黄芪注射液治疗老年心力衰竭疗效观察[J].临床医学,2003, 23(4):54-55
[58]邢鹏云,贾连旺.黄芪注射液辅助治疗充血性心力衰竭的疗效分析[J].心血管康复医学杂志,2003,12(1):82-83
[59]罗贤初.黄芪注射液治疗充血性心力衰竭30例临床观察[J].中国中医急症,2003,12(1):35
[60]王红梅,高晟.黄芪注射液治疗老年充血性心力衰竭[J].天津中医,2002,19(6):21
[61]李长泉,朱小霞.黄芪注射液辅助治疗慢性充血性心力衰竭疗效观察[J].医学理论与实践,2002,15(11):1277-1278
[62]周宗梅,蔡爱玲,罗昌雄,等.黄芪注射液辅助治疗冠心病心力衰竭的临床观察[J].湖北中医杂志,2002,24(9):11-12
[63]朱春玲,彭红英.黄芪注射液在慢性肾功能衰竭尿毒症合并心力衰竭治疗中的应用[J].贵州医药,2002,26(8):762
[64]王莉,陈铁梅.黄芪注射液治疗右心衰竭64例疗效观察[J].齐齐哈尔医学院学报,2002,23(6):621
[65]许国星,孙丽娟.黄芪注射液治疗肺心病并发心衰疗效观察[J].济宁医学院学报,2002,25(2):65
[66]蔺翠兰,王红,史慧玲.黄芪注射液辅助治疗肺心病心力衰竭58例[J].中医药学报,2002,30(3):15
[67]孙洪.黄芪注射液治疗慢性心功能不全40例疗效观察[J].中国中医药科技,2002,9(3):187
[68]尹绢,魏群.黄芪注射液治疗肺原性心脏病心力衰竭疗效观察[J].河北中医,2002,24(4):308-309
[69]章大进.黄芪注射液治疗肺心病心衰42例疗效观察[J].现代中西医结合杂志,2002,11(5):408
[70]闫惠珍,闫晓婷.黄芪注射液治疗肺心病心力衰竭80例[J].中国康复,2002,17(2):112
[71]陈启华,黄芪注射液伍用钾镁液治疗心衰疗效观察[J].心血管康复医学杂志,2001,10(6):554-555
[72]尚玉红,肖艳.黄芪注射液治疗充血性心力衰竭的临床研究[J].河南中医药学刊,2001,16(6):32-33
[73]周智林,俞娉,林玎,等.黄芪注射液治疗充血性心力衰竭的疗效研究[J].中国中西医结合杂志,2001,21(10):747-749
[74]马战平,程小红,王凌.黄芪注射液辅佐治疗慢性肺心病心衰86例[J].陕西中医,2001,22(10):579-580
[75]原广平.黄芪注射液治疗慢性心力衰竭的疗效观察.[J],中国医院药学杂志,2001,21(9S):85
[76]张虎.黄芪注射液佐治肺心病心力衰竭66例[J].中国中西医结合急救杂志,2001,8(5):313
[77]卢延生.不同剂量黄芪注射液治疗心衰疗效对比[J].江苏中医,2001,22(9):45
[78]潘国良,马卫琴.黄芪注射液治疗肺原性心脏病并心力衰竭[J].浙江中西医结合杂志,2001,11(8):496-497
[79]李伟,赵卫.黄芪注射液治疗慢性充血性心力衰竭50例临床观察[J].浙江中西医结合杂志,2001,11(5):307-308
[80]胡锦章,甘结友.黄芪注射液治疗慢性心衰30例[J].中国临床药理学与治疗学,2001,6(1):78
[81]林宏初,吴恒莲,阮雪玲.黄芪注射液治疗慢性肾衰竭合并心力衰竭的临床疗效[J].中国中西医结合肾病杂志,2000,1(4):218-220
[82]褚瑰翔,彭新念.黄芪注射液辅助治疗难治性心力衰竭[J].湖北中医杂志,2000,22(10):29-30
[83]高旭.黄芪注射液对充血性心力衰竭患者心功能及血液流变学的影响[J].中国临床药理学与治疗学杂志,2000,5(3):257-258
[84]王健,盛净,陈元美,等.生脉注射液和黄芪注射液对冠心病心功能不全患者舒张功能的影响[J].中国综合临床,2000,16(9):702-703
[85]邓桂银,周素清,李晓光.黄芪注射液治疗难治性心力衰竭30例[J].中国药业,2000,9(8):30
[86]杨继荣,谢其中.黄芪注射液治疗慢性心功能不全疗效观察[J].现代中西医结合杂志,2000,9(12):1131
[87]钱海凌,黄立武.大剂量黄芪注射液治疗难治性心衰的临床观察[J].辽宁中医杂志,2000,27(5):202-203
[88]张力军,王桂霞,张关生.黄芪注射液佐治肺心病心衰疗效观察[J].西藏医药杂志,2000,21(2):14-15
[89]王俐.黄芪注射液与硝酸甘油合用治疗心衰疗效观察[J].重庆医学,2000,29(1):71-72
[90]何居仁,马丹军.黄芪注射液治疗充血性心力衰竭作用机理探讨[J].上海医药,2000,21(1):25-26
[91]曾群英.黄芪注射液治疗重症充血性心力衰竭的疗效研究[J].中药药理与临床,1999,15(6):36-38
[92]包祥宁.黄芪注射液治疗老年充血性心衰[J].中药药理与临床,1999,15(6):39-40
[93]文旺秀,严夏,吴焕林.黄芪注射液治疗慢性心力衰竭的疗效观察[J].中药药理与临床,1999,15(6):38-39
[94]钱嘉宏.大剂量黄芪注射液治疗充血性心力衰竭的疗效观察[J].江苏临床医学杂志,1999,3(6):545-546
[95]周波,张小燕,常中凡,等.黄芪注射液辅助治疗肺心病心力衰竭64例[J].中国新药与临床杂志,1999,18(6):374-375
[96]王兵,陈康乐,邓世周,等.常规疗法加黄芪注射液治疗肺心病并心衰及呼衰51例观察[J].实用中医药杂志,1999,15(10):21-22
[97]王世茹,李吉荣,段国威.黄芪注射液用于妊高征性心脏病、心功能不全的疗效观察[J].临床荟萃,1999,14(S):241
[98]高金柱.黄芪注射液治疗心力衰竭的临床观察[J].临床荟萃,1999,14(S):242
[99]孙跃东,杨丽华.比较黄芪注射液和心先安对充血性心力衰竭的疗效[J].临床荟萃,1999,14(S):235-236
[100]崔伟,刘敬友.黄芪注射液治疗冠心病心功能不全疗效观察[J].实用中西医结合杂志,1998,11(10):896
[101]孙琼,张宝陵,孙立勤.黄芪注射液治疗肺心病心衰42例[J].中国中医急症,1998,7(5):206
[102]杨秀丽,张朝霞.地奥黄芪注射液辅助治疗扩张型心肌病充血性心力衰竭疗效观察[J].临床医学,1998,18(9):38
[103]杨忠奇,刘明平.黄芪注射液在治疗充血性心力衰竭时对洋地黄中毒发生率的影响[J].中药新药与临床药理,1998,9(2):80-81
[104]李绍敏,汪小红.黄芪注射液治疗严重充血性心力衰竭疗效及其对QT离散度的影响[J].中西医结合实用临床急救,1998,5(3):123-125
[105]王东红.黄芪注射液治疗慢性肺心病心衰73例[J].江苏中医,1998,19(3):18-19
[106]赵智深,刘福喜,杨留振.黄芪注射液辅助治疗充血性心力衰竭.[J],实用中西医结合杂志,1998,11(1):26
[107]张兴家,范丽华,张世英,等.黄芪注射液治疗慢性肾功能不全并心力衰竭临床研究[J].长春中医学院学报,1997,13(4):18
[108]田浪,艾俊,邓成明.黄芪注射液与巯甲丙脯酸联用治疗难治性慢性肺原性心衰46例临床观察.[J],上海医药,1997,(11):16
[109]杨芝芸.黄芪注射液治疗高原肺心病心衰65例[J].辽宁中医杂志,1997,24(6):261
[110]李绍敏,吕美农.黄芪注射液配合治疗肺心病心衰30例[J].安徽中医学院学报,1997,16(2):19-20
[111]李黔云,吴洋.黄芪注射液治疗慢性心衰68例疗效观察[J].上海医药,1997,(1):19
[112]田凤军,陈亚丽,何秀月,等.黄芪注射液治疗肺心病心力衰竭疗效观察[J].河北中西医结合杂志,1997,6(1):45-46
[113]翟理黄,王梅,岳金明,等.黄芪注射液治疗充血性心力衰竭的临床观察[J].上海医药,1995,(11):10-12
[114]杨鑫.黄芪注射液治疗老年人难治性心力衰竭的临床研究[J].齐齐哈尔医学院学报,2008,29(12):1464
[115]惠树林,郝文辉.黄芪注射液治疗慢性肺源性心脏病心力衰竭疗效观察[J].现代中西医结合杂志,2008,17(13):1965
[116]吕俊.西药联合黄芪注射液治疗慢性充血性心力衰竭36例观察[J].实用中医药杂志,2008,24(3):164-165
[117]孟捍华,马敏杰.黄芪注射液对慢性充血性心力衰竭治疗作用的观察[J].中医药临床杂志,2008,20(1):40-41
[118]林果为,沈富民.现代临床流行病学[M].上海:复旦大学出版社,2000.
[119]Cowie MR,Wood DA,Coats AJS,et al.Survival of patients with a new diagnosis of heart failure:a population based study[J].Heart,2000,83(5):505-510.
[120]鄢立新,唐卫文,付铁军,等 不同厂家产黄芪注射液中黄芪甲苷的含量考察[J].中成药,2004,26(8):626-628.
[121]吴晓放,高日胜,许文年,等.黄芪注射液与4种输液的配伍实验[J].2000,18(6):374-376.
[122]王家良.临床治疗性研究的设计与评价[J].中华医学杂志,1999,79(2):94-96.
[123]刘建平.循证医学方法与中医疗效评价[J].首都医科大学学报,2007,28(2):212-215.
[124]Curtis JP,Sokol SI,Wang Y,et al.The association of left ventricular ejection fraction,mortality,and cause of death in stable outpatients with heart failure[J].J Am Coll Cardiol,2003,42(4):736-742.
[125]Koyama Y,Takeishi Y,Arimoto T,et al.High serum level of pentosidine,an advanced glycation end product(AGE),is a risk factor of patients with heart failure[J].J Card Fail,2007,13(3):199-206.
[126]王新房.超声心动图学[M].北京:人民卫生出版社:278-281.
[127]苏国研.中药临床疗效评价标准的思考[J].国际医药卫生导报,2003,2:119-120.
[128]于嘉,谢雁鸣.中医卫生经济学评价的研究思路与方法[J].中国中医药信息杂志,13(6):106-108.
[129]Dokainish H.Combining tissue Doppler echocardiography and B-type natriuretic peptide in the evaluation of left ventricular filling pressures:review of the literature and clinical recommendations[J].Can J Cardiol,2007,23(12):983-989.
[130]张宏伟,唐金陵,刘建平.临床试验中的对照设置[J].中医杂志,2007,48(2):125-128.
[131]魏莉,苏振军,关富山.黄芪注射液治疗小儿脑瘫的随机、双盲临床研究[J].2008,6(3):234-236.
[132]刘鸣,张世洪.新知识:临床试验中的意向处理分析[J].英国医学杂志:中文版,2001,4(4):223-224.
[133]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095.
[1]林谦,农一兵,黄启福.从心肌能量代谢探讨慢性心力衰竭心气虚证的实质[J].北京中医药大学学报,2007,7(7):445-446,474.
[2]苏敬泽,林谦,农一兵.黄芪组分配伍对血管紧张素Ⅱ致肥大心肌细胞模型线粒体活力的影响[J].2007,26(11):742-744.
[3]殷仁富,陈金明.心脏能量学-代谢与治疗[M].第1版.上海:第二军医大学出版社,2002:151-183.75.177.
[4]Harary I,Farkey B.In vitro studies of single isolated beating heart cell[J].Science,1960,131:1674-1675.
[5]H(u|¨)gel S,Horn M,de Groot M,et al.Effects of ACEInhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction[J].Am J Physiol,1999,277(6 Pt 2):H2167-H2175.
[6]Hammerschmidt S,Bell M,B(u|¨)chler N,et al.Acute changes of myocardial creatine kinase gene expression under β-adrenergic stimulation[J].Biochim Biophys Acta,,2000,1502(3):471-480.
[7]李兵.缺氧过程中大鼠心肌线粒体能量代谢和腺苷酸转位酶活性及表达的研究.[D],2004:12.30.
[8]Rosamond W,Flegal K,Furie K,et al.Heart disease and stroke statistics-2008 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J].Circulation,2008,117(4):e25-e 146.
[9]Holubarsch CJ,Rohrbach M,Karrasch M,et al.A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure:the ERGO(etomoxir for the recovery of glucose oxidation) study[J].Clin Sci(Lond),2007,113(4) 205-212.
[10]赵耐久,张玉东.血管紧张素Ⅱ受体拮抗剂与心力衰竭患者心室重塑的研究进展[J].中华现代临床医学杂志,2005,3(11):1041-1042.
[11]Lijnen P,Petrov V.Renin-angiotensin system,hypertrophy and gene expression in cardiac myocytes[J].J Mol Cell Cardiol,1999,31(5):949-970.
[12]Mathur A,.Hong Y,Kemp BK,et al.Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes[J].Cardiovasc Res,2000,46(1):126-138.
[13]Sharma AK,Dhingra S,Khaper N,et al.Activation of apoptotic processes during transition from hypertrophy to heart failure in guinea pigs[J].Am J Physiol Heart Circ Physiol,2007,293(3):H1384-H1390.
[14]Choudhary R;Baker KM,Pan J.All-trans retinoic acid prevents angiotensin Ⅱ- and mechanical stretch-induced reactive oxygen species generation and cardiomyocyte apoptosis[J].J Cell Physiol,2008,215(1):172-181.
[15]陈丽芬.缺氧对大鼠脑线粒体氧化呼吸功能和ANT活性及异构体表达的影响[D].2004:44.
[16]Portman MA.The adenine nucleotide translocator:regulation and function during myocardial development and hypertroph[J].Clin Exp Pharmacoi Physiol,2002,29(4):334-338.
[17]D(o|¨)rner A,Olesch M,Giessen S,et al.Transcription of the adenine nucleotide translocase isoforms in various types of tissues in the rat[J].Biochimicaet Biophysica Acta,1999,1417(1):16-24.
[18]李兵,柳君泽,陈丽芬.缺氧对大鼠心肌线粒体能量代谢和腺苷酸转位酶活性的影响[J].中国病理生理杂志,2006,22(3):460-463.
[19]Hammerschmidt S,Bell M,B(u|¨)chler N,et al.Acute changes of myocardial creatine kinase gene expression under beta-adrenergic stimulation[J].Biochim Biophys Acta,2000,1502(3):471-480.
[20]De Sousa E,Veksler V,Minajeva A,et al.Subcellular creatine kinase alterations.Implications in heart failure[J].Circ Res,1999,85(1):68-76.
[21]Saupe KW,Spindler M,Hopkins JC,et al.Kinetic,thermodynamic,and developmental consequences of deleting creatine kinase isoenzymes from the heart.Reaction kinetics of the creatine kinase isoenzymes in the intact heart[J].J Biol Chem,2000,275(26):19742-19746.
[22]Lygate CA,Fischer A,Sebag-Montefiore L,et al.The creatine kinase energy transport system in the failing mouse heart[J],J Mol Cell Cardiol,2007,42(6):1129-1136.
[23]Neubauer S,Frank M,Hu K,et al.Changes of creatine kinase gene expression in rat heart post-myocardial infarction[J].J Mol Cell Cardiol,1998,30(4):803-810.
[24]Hoang CD,Zhang J,Payne RM,et al.Post-infarction left ventricular remodeling induces changes in creatine kinase mRNA and protein subunit levels in porcine myocardium[J].Am J Pathol,1997,151(1):257-264.
[25]管佳,毕志明,李萍.黄芪皂苷注射液指纹图谱的研究[J].中国中药杂志,2006,31(10):807-809.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |